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ICa,L L-type calcium current
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IKp potassium plateau current
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IKs slowly activated delayed rectifier potassium current
IKur ultrarapid potassium current
INa sodium current
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Iti transient inward potassium current
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JLNS Jervell-Lange-Nielsen syndrome
KCNA5 potassium voltage-gated channel, shaker-related subfamily, member 5 gene
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KCNE1 potassium voltage-gated channel, Isk-related family, member 1 gene
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RyR/RyR 1 and 2 ryanodine receptor gene/protein type 1 or 2
SCD sudden cardiac death
SCN4B voltage-gated sodium channel, type IV, beta
SCN5A sodium channel alpha subunit gene
SERCA2a sarcoplasmic reticulum Ca2+ ATPase
SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1
SNP single-nucleotide polymorphism
SOICR store overload-induced Ca2+ release
SR sarcoplasmic reticulum
SUD sudden unexplained death
TdP torsades de pointes
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Inherited cardiac arrhythmia disorders are rare but clinically important, as they underlie sudden cardiac
deaths among otherwise healthy young individuals. Congenital long QT syndrome (LQTS) with an
estimated prevalence of 1:2000-1:10 000 manifests with prolonged QT interval on electrocardiogram and
risk for ventricular arrhythmias and sudden death. Several ion channel genes and hundreds of mutations in
these genes have been identified to underlie congenital LQTS. In Finland, four LQTS founder mutations
of potassium channel genes account for up to 40-70% of genetic spectrum of LQTS. Acquired LQTS has
similar clinical manifestations, but often arises from usage of QT-prolonging medication or electrolyte
disturbances. A prolonged QT interval is associated with increased morbidity and mortality not only in
clinical LQTS but also in patients with ischemic heart disease and in the general population.
The principal aim of this study was to estimate the actual prevalence of LQTS founder mutations in
Finland and to calculate their effect on QT interval in the Finnish background population. Using a large
population-based sample of over 6000 Finnish individuals from the Health 2000 Survey, we identified
LQTS founder mutations KCNQ1 G589D (n=8), KCNQ1 IVS7-2A>G (n=1), KCNH2 L552S (n=2), and
KCNH2 R176W (n=16) in 27 study participants. This resulted in a weighted prevalence estimate of 0.4%
for LQTS in Finland. Using a linear regression model, the founder mutations resulted in a 22- to 50-ms
prolongation of the age-, sex-, and heart rate-adjusted QT interval. Collectively, these data suggest that
one of 250 individuals in Finland may be genetically predisposed to ventricular arrhythmias arising from
the four LQTS founder mutations. In a separate study, LQTS founder mutations were identified in a
subgroup of acquired LQTS, providing further evidence that congenital LQTS gene mutations may
underlie acquired LQTS.
Disease-causing LQTS mutations, although enriched in the Finnish population, are rare and cannot
account for the population burden of severe ventricular arrhythmias. Even subtle changes in QT interval
duration caused by common gene variants may be important at the population level. The effect of
common LQTS gene variants on QT interval was studied in the Health 2000 material using linear
regression. A KCNE1 D85N minor allele with a frequency of 1.4% was associated with a 10-ms
prolongation in adjusted QT interval and could thus identify individuals at increased risk of ventricular
arrhythmias at the population level. In addition, the previously reported associations of KCNH2 K897T,
KCNH2 rs3807375, and NOS1AP rs2880058 with QT interval duration were confirmed in the present
study.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized by exercise-induced
ventricular arrhythmias in a structurally normal heart and results from defects in the cardiac Ca2+
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signaling proteins, mainly ryanodine receptor type 2 (RyR2). In a patient population of typical CPVT,
RyR2 mutations were identifiable in 25% (4/16) of patients, implying that noncoding variants or other
genes are involved in CPVT pathogenesis. A 1.1 kb RyR2 exon 3 deletion was identified in two patients
independently, suggesting that this region may provide a new target for RyR2-related molecular genetic
studies. Since CPVT is associated with high mortality, a search for RyR2 mutations in a cohort of sudden
cardiac death patients was performed. Two novel RyR2 mutations (R3570W and G2145R) showing a
gain-of-function defect in vitro were identified in three victims of sudden cardiac death. The two carriers
of R3570W were distant relatives and showed mildly enlarged and dilated hearts at autopsy. None of the
surviving RyR2 R3570W carriers featured the exercise-induced ventricular arrhythmias typical of CPVT,
but mild structural abnormalities and resting ventricular arrhythmias were apparent in a few relatives.
In conclusion, the four LQTS founder mutations leading to considerable QT interval prolongation appear
to be exceptionally prevalent in the Finnish population and may provide a rationale for population
screening for arrhythmia susceptibility in the future. In addition, common LQTS variants, KCNE1 D85N
in particular, appear to modulate QT interval duration at the population level. Not all RyR2 mutations lead
to a typical, highly penetrant CPVT phenotype, underscoring the relevance of tailored risk stratification of
a RyR2 mutation carrier.
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INTRODUCTION
Cardiac ion channelopathies are a set of inherited disorders characterized by electrical instability of the
heart, typically in the absence of structural heart disease. The spectrum of the disease phenotypes is wide,
the most malignant arrhythmia syndromes being those that cause ventricular tachycardia. Although rare,
the inherited ventricular arrhythmia syndromes are of clinical importance as they may underlie morbidity
and mortality at a young age.
The last two decades have revolutionized knowledge of inherited arrhythmia disorders. The first clinical
descriptions of familial arrhythmia disorders emerged in the late 1950s, when Jervell et al. and Levine et
al. described pedigrees with unusually long QT intervals on electrocardiogram, structurally normal hearts
and increased risk of sudden death (Jervell et al. 1957, Levine et al. 1958). However, the underlying
causes remained unknown for decades. The linkage study by Keating et al. in 1991 identified the first
long QT syndrome disease locus (Keating et al. 1991), and subsequent studies using a candidate gene
approach and/or linkage analysis have led to the identification of several genes and hundreds of disease-
causing mutations in cardiac ion channel disorders (Priori et al. 2008). Similar approaches have been used
to unravel the genetic background of other inherited arrhythmia disorders. Unquestionably, the
completion of the human genome project at the beginning of this decade (Lander et al. 2001, Venter et al.
2001) has laid the cornerstone for these recent advances in molecular medicine. Characterization of
familial gene defects in these pedigrees enables the genetic testing of yet asymptomatic relatives, which is
of high priority if the disorder is malignant and treatment available. In addition, identification of unusual
genotype-phenotype correlations, new disease genes, and subsequent in vitro and murine studies on
disease mechanisms have brought new insights into the biological processes underlying disease pathology
and provide targets for therapeutic innovations.
The increasing phenotypic complexity underlying inherited cardiac ion channelopathies has overwhelmed
researchers in the field since the first description of variable penetrance in long QT syndrome (LQTS)
(Vincent et al. 1992). Apparently, both genetic and environmental factors interact with the particular
pathogenic mutation and contribute to disease phenotype. Identification of modifying factors could have
direct implications for risk stratification of a mutation carrier. Ultimately, these relatively common
genetic variants could also identify individuals at increased risk for arrhythmias at the population level.
The development of high-throughput genotyping techniques has enabled studies on large sample sizes
powered to detect genetic modifying factors of arrhythmia susceptibility. Studies have not necessarily
focused directly on disease phenotype, but utilized intermediate phenotypes, such as QT interval duration
in LQTS. The aim of this study was to identify both rare and common genetic variants predisposing to
severe ventricular arrhythmias in clinical samples and at the population level.
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REVIEW OF THE LITERATURE
1   ELECTRICAL ACTIVITY OF THE HEART
1.1   Cardiac action potential
The heart is an electromechanical pump that depends on action potential generation and contraction,
followed by relaxation and a period of refractoriness until the next impulse is generated (Nerbonne et al.
2005). Myocardial electrical activity is generated in the pacemaker cell of the sinoatrial node and then
mediated through the atria and atrioventricular node to conducting Purkinje fibers and ultimately to the
ventricular myocardium (Nerbonne et al. 2005). Cardiac excitability results from a highly coordinated
balance of both depolarizing and repolarizing ion currents (Marban 2002). Cardiac ion channels that
selectively mediate the flow of ions across biological membranes have variable expression in specific
regions of the heart, thus resulting in a distinct action potential morphology (Roden et al. 2002). In
ventricular myocytes, the action potential exhibits a sharp depolarizing upstroke in phase 0 due to influx
of Na+ (Figure 1) (Berne 1998), which is followed by K+ efflux, producing early repolarization in phase 1.
The slowly decaying plateau in phase 2 results from Ca2+ influx from the extracellular space and is


























Figure 1. Cardiac action potential in ventricular myocytes comprising phases 0-4. Cardiac ion currents (left panel)
and the genes (right panel) encoding the respective ion channels.
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Cardiac repolarization is based on the intricate balance of predominantly outward K+ currents (Berne
1998). The IK1 current is active at negative potentials and restores the baseline potential (Marban 2002).
The transient outward current Ito is responsible for the initial notch of repolarization in phase 1, thus
influencing the duration of the action potential (Marban 2002). The delayed rectifier IK currents,
composed of rapid (IKr) and slow (IKs) components, are the major determinants of final repolarization in
phase 3 (Marban 2002). The restoration of ion concentrations is achieved by the action of Na+K+ ATPase
and Na+/Ca2+ exchanger, which pump Na+ into the extracellular space and in exchange restore K+ and
Ca2+ ions in the cardiomyocyte (Berne 1998).
1.2   Cardiac excitation-contraction coupling
Calcium influx via voltage-gated L-type Ca2+ channels in phase 2 of the cardiac action potential initiates
Ca2+ release from the sarcoplasmic reticulum, a phenomenon known as Ca2+-induced Ca2+ release (CICR)
(Bers 2002). The calcium release is transmitted via sarcoplasmic ryanodine receptor type 2 (RyR2)
receptor complex, comprising several associated proteins such as triadin, junctin, and calsequestrin (Bers
2002). The elevated free intracellular Ca2+ concentration allows the binding of Ca2+ to troponin C,
initiating the contraction of myofilaments (Bers 2002). The cardiac contraction is terminated by
transmitting cytosolic free Ca2+ ions back to the sarcoplasmic reticulum (SR) via the SR Ca2+ ATPase
(SERCA2a) pump (Bers 2002). In addition, the Na+/Ca2+ exchanger and Ca2+ ATPase on the sarcolemma
as well as a mitochondrial Ca2+ pump contribute to the elimination of free Ca2+, and thus, the initiation of
myocardial relaxation (Bers 2002).
1.3   Cardiac ion channels
Ion channels are pore-forming proteins that control a voltage gradient across the plasma membrane,
resulting in either depolarization or hyperpolarization of the cell (Celesia 2001). Most ion channels are
gated and classified according to the control mechanisms required for channel opening such as voltage,
ligand binding, G-protein interaction, or mechanical gating (Felix 2000). Voltage-gated ion channels are
critical for the appropriate electrophysiologic behavior of the heart. The cardiac ion channel subunits are
each encoded by a single gene. The pore-forming #-subunit is often sufficient to generate an ion current,
but the coordinated function of #-subunits, accessory "-subunits, and multiple modulating proteins is
necessary for appropriate trafficking, phosphorylation, and posttranslational modifications of the
channels (Roden et al. 2002). The #-subunit consists of six hydrophobic S1-S6 segments embedded in the
plasma membrane (Felix 2000). The pore region resides between segments S5 and S6, while the highly
conserved S4 contains several positive amino acid residues that function as the voltage sensor of the
channel (Felix 2000). A tetramer of identical #-subunits is required to generate a functional voltage-gated
K+ channel with ion-permeant ion pores (Roden et al. 2002), while in Na+ and Ca2+ channels the same
channel structure consists of four repeats of S1-S6 transmembrane regions. In addition to the voltage-
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gated cardiac ion channels, the inward rectifier K+ channels are crucial for the electrical activity of the
heart and present a more primitive channel structure, with two membrane-spanning segments and the
intervening pore region (Roden et al. 2002).
































Figure 2. Schematic representation of the transmembrane topology of voltage-gated K+, Na+, and Ca2+ channels.
The potassium channel is composed of four identical #-subunits, each comprising six transmembrane domains (S1-
S6) and the interlinking regions. The S1-S6 segment of the potassium channel is homologous to the four Na+ and
Ca2+ channel domains. The more primitive K+ channels consist of either one or two transmembrane segments. The
amino (NH2) and carboxy (COOH) termini are presented with N and C, respectively. P refers to pore-forming
regions.
1.4   Mechanisms of arrhythmias
Re-entry and triggered activity are the primary mechanisms for disturbances in cardiac rhythm. In re-
entry, the electric impulse re-excites a region that has previously been activated (Berne 1998). Triggered
activity is caused by both early and delayed afterdepolarizations, EADs and DADs, respectively (Berne
1998). EADs occur at the end of the plateau (phase 2) or in phase 3, before the cell is fully repolarized,
and are most likely to appear at low heart rates (Berne 1998). Prolonged action potential is hypothesized
to allow the Ca2+ channels of the plateau phase to be reactivated and to trigger EADs (Berne 1998). The
transmural dispersion of repolarization (TDR) of the myocardial wall and the development of EADs are
the substrate for the torsades de pointes arrhythmia encountered in LQTS (Antzelevitch 2004). By
contrast, DADs occur at relatively high heart rates and are associated with elevated intracellular Ca2+
concentrations (Berne 1998). The rise in intracellular Ca2+ causes a release of sarcoplasmic Ca2+, which in
turn activates Na+ and K+ passage into the cell (Berne 1998). The net effect of this transient inward
current Iti is DADs of the sarcolemma, leading to triggered activity (Schlotthauer et al. 2000).
1.5   Repolarization components on electrocardiogram
Disturbed cardiac excitability is detectable on surface electrocardiogram (ECG), which represents an
average of the electrical gradients (Marban 2002). The QT interval, determined as the time from the onset
of the QRS complex to the end of the T wave, shows the duration of ventricular depolarization and
repolarization. The ventricular myocardium consists of several myocardial cell types with diverse
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electrophysiological characteristics (Antzelevitch 2004). M cells present a smaller slowly activating
delayed rectifier potassium current (IKs) and a larger late INa current than epicardial and endocardial
myocytes (Yan et al. 2003). The density of rapidly activating delayed rectifier potassium current (IKr) is,
in turn, even across the ventricular wall (Yan et al. 2003). Alterations in the IKs:IKr ratio are attributable to
TDR, thus predisposing to abnormal ventricular repolarization (Yan et al. 2003). Apparently, the
preferential prolongation of action potential in M cells underlies the increase in TDR and QT interval
prolongation (Shimizu et al. 2000) that has been shown to be associated with increased mortality in LQTS
patients (Moss et al. 1991), in coronary artery disease patients (Schwartz et al. 1978, Puddu et al. 1986)
and in the general population (Algra et al. 1991, Schouten et al. 1991, Karjalainen et al. 1997). T wave
alternans refers to T wave fluctuations in morphology, amplitude, and polarity, and is associated with
changes in TDR, and thus, with ventricular arrhythmias (Narayan 2006).
2   SPECTRUM OF INHERITED CARDIAC ION CHANNELOPATHIES
Following the initial description of potassium channel gene defects and their association with LQTS
(Curran et al. 1995), several cardiac disorders have been demonstrated to result from ion channel
dysfunction. These include purely arrhythmogenic disorders, but also diseases with apparent structural
abnormalities of the myocardium (Table 1). The majority of the disorders are caused by mutated ion
channels, but also defects in channels subunits and associated proteins may lead to similar disease
phenotypes. A peculiar aspect of cardiac ion channelopathies is considerable overlap in genetic and
phenotypic characteristics of the disorders. The phenomenon is specifically recognized in cardiac sodium
channelopathies, where mutations in the sodium channel alpha subunit gene (SCN5A) have been shown
to result in de- and repolarization abnormalities (LQTS3) (Wang et al. 1995), idiopathic ventricular
fibrillation with distinct ECG patterns (Brugada syndrome 1) (Brugada et al. 1992), atrial fibrillation and
dilated cardiomyopathy (McNair et al. 2004), and in a variety of conduction abnormalities (Schott et al.
1999, Tan et al. 2001, Wang et al. 2002). Interestingly, even a particular mutation in the SCN5A gene
may lead to multiple clinical phenotypes (Kyndt et al. 2001, Grant et al. 2002, Smits et al. 2005). A few
in vitro electrophysiological studies (Veldkamp et al. 2000, Remme et al. 2006) suggest that a specific
SCN5A mutation may indeed result in a variety of defects, explaining part of the phenotypic diversity.
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Table 1. Spectrum of cardiac ion channel disorders.
Disorder Sub-
type




1 11p15.5 KCNQ1 Kv7.1 # IKs$% (Chen et al. 2003)
2 21q22.1 KCNE2 MiRP1 " IKs % (Yang et al. 2004)
3 17q23 KCNJ2 Kir2.1 # IK1 % (Xia et al. 2005)
4 1q21.1 GJA5 Connexin 40* Cell adhesion & (Gollob et al. 2006)
5 21q22.1 KCNE1§ minK " IKs & (Lai et al. 2002)
6 12p13 KCNA5 Kv1.5 # IKur & (Olson et al. 2006)
BRUGADA SYNDROME
1 3p21 SCN5A Nav1.5 # INa & (Chen et al. 1998)
2 3p24 GPD1L G3PD1L* INa & (London et al. 2007)
CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA
1 1q42-43 RyR2 RyR2 SR Ca2+ leak % (Laitinen et al. 2001)
(Priori et al. 2001)
2 1p13.3 CASQ2 Calsequestrin* SR Ca2+ leak % (Lahat et al. 2001b)
CONDUCTION DEFECTS
3p21 SCN5A Nav1.5 # INa & (Schott et al. 1999)
CONGENITAL SICK SINUS SYNDROME
3p21 SCN5A Nav1.5 # INa & (Benson et al. 2003)
FAMILIAL WOLFF-PARKINSON-WHITE SYNDROME
7q36.1 PRKAG2 AMPK !2* INa$% ? (Gollob et al. 2001)
IDIOPATHIC VENTRICULAR FIBRILLATION
3p21 SCN5A Nav1.5 # INa & (Akai et al. 2000)




Kv11.1 # IKr % (Brugada et al. 2004)
2 11p15.5 KCNQ1 Kv7.1 # IKs$% (Bellocq et al. 2004)
3 17q23 KCNJ2 Kir2.1 # IK1 % (Priori et al. 2005)
* Refer to ion channel-associated proteins. § association data of gene polymorphism with the clinical phenotype, no
direct evidence of disease-causing mutations. & refers to loss-of-function defect, % refers to gain-of-function defect.
The phenotypes of cardiac ion channelopathies are overlapping. Modified from (Lehnart et al. 2007).
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 3   LONG QT SYNDROME
3.1   Clinical manifestations of LQTS
Congenital long QT syndrome (cLQTS) is an inherited cardiac repolarization disorder characterized by
QT interval prolongation on surface ECG and risk for ventricular tachyarrhythmias and sudden death in
the presence of physical or emotional stress (Priori 2004, Schwartz 2006) or while asleep (Schwartz et al.
2001). Congenital LQTS is a rare disorder, with recent prevalence estimates of 0.01% (Ackerman et al.
2003) to 0.05% (Hofman et al. 2007). A distinct feature of LQTS is the torsades de pointes arrhythmia
(Viskin 1999) that manifests with a twisting QRS complex around the isoelectric baseline and may
develop to ventricular fibrillation and sudden death. The mean age of onset in LQTS is 12 years, but
symptoms may occur from the first year of life to the late fifties and sixties (Zipes et al. 2006).
The diagnosis of LQTS is based on the measurement of the QT interval on surface ECG. The upper limit
for heart rate–corrected QT interval (QTc Bazett) is 440 ms for men (Vincent et al. 1992) and 460 ms for
women (Schwartz 2006). However, a significant overlap occurs in the QTc intervals of LQTS patients
and healthy individuals. In a study by Vincent et al. (1992), the QTc intervals of genetically affected
LQTS patients ranged from 410 ms to 590 ms, as opposed to 380 ms to 470 ms among mutation
noncarriers (Vincent et al. 1992). The Schwartz scoring system (Schwartz 2006) (Table 2) is suitable for
situations where the QTc interval is borderline prolonged and/or symptoms such as stress-induced
syncope are absent. The Schwartz diagnostic criteria are based on repolarization abnormalities on ECG,
occurrence of symptoms, and the presence of family history, providing a probability score of LQTS in a
given individual. A score of ' 3.5 points is associated with a high probability of LQTS, and ( 1 point with
a low probability of the disorder (Schwartz 2006).
The Schwartz criteria has high specificity (99%) but low sensitivity (19%) (Swan et al. 1998, Hofman et
al. 2007), and therefore, analysis of QTc >430 ms alone with a specificity of 86% and a sensitivity of
72% has been proposed to be sufficient to distinguish mutation carriers from noncarriers (Hofman et al.
2007). In addition, exercise stress test provides information on QT interval response to physical stress,
and may be used to improve the clinical diagnosis of LQTS1-2 (Swan et al. 1999b). Echocardiography is
useful only in ruling out other cardiac disorders. Even though LQTS is a clinical diagnosis, constantly
developing genetic testing measures enable precise molecular genetic diagnosis, and thus, provide tools
for risk stratification.
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Table 2. The Schwartz scoring system for LQTS 1985-2006 (Schwartz et al. 1985, Schwartz et al. 1993,
Schwartz 2006)
FINDING SCORE
ECG A  QTc > 480 ms 3
460 – 470 ms 2
450 – 459 ms (male) 1
B  Torsades de pointes* 2
C  T wave alternans 1
D  Notched T wave in 3 leads 1
E  Low heart rate for age§ 0.5
CLINICAL HISTORY A  Syncope* with stress 2
without stress 1
B  Congenital deafness 0.5
FAMILY HISTORY^ A  Family members with definite LQTS 1
B  Sudden unexplained death < 30 years
among immediate family members
0.5
* Mutually exclusive, § resting heart rate below the 2nd percentile for age, ^ the same family member can not be
counted in A and B.
3.2   Molecular genetics of LQTS
Clinical LQTS was first characterized in the 1950s when Jervell and Lange-Nielsen described a family
with syncopal spells and prolonged QT interval in association with hearing loss (Jervell et al. 1957).
However, it was not until 1995 that the first underlying cause of LQTS was identified as the mutated
cardiac potassium channel gene KCNH2 (HERG) (Curran et al. 1995). Today, ten genes and over six
hundred mutations have been identified to cause congenital LQTS (Priori et al. 2008) (Table 3). The
majority of these genes code for cardiac ion channel proteins, but also genes affecting regulatory proteins
in the cardiac macromolecular assemblies underlie cLQTS (Mohler et al. 2003, Vatta et al. 2006,
Medeiros-Domingo et al. 2007). LQTS is generally inherited in an autosomal dominant fashion (i.e.
Romano-Ward syndrome, RWS) (Romano 1965), with the exception of extremely rare homozygote
carriers of potassium channel gene mutations, which also result in congenital deafness (i.e. Jervell and
Lange-Nielsen syndrome, JLNS) (Jervell et al. 1957).
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LQTS1 11p15.5 KCNQ1 Kv7.1 # IKs & (Wang et al. 1996)
LQTS2 7q35 KCNH2/HERG Kv11.1 # IKr$& (Curran et al. 1995)
LQTS3 3p21 SCN5A Nav1.5 # INa$% (Wang et al. 1995)
LQTS4 4q25 ANK2 Ankyrin-B* INa,K & INCX$& (Mohler et al. 2003)
LQTS5 21q22.1 KCNE1 minK " IKs$& (Splawski et al. 1997)








12p13.3 CACNA1C Cav1.2 #1c ICa,L$% (Splawski et al. 2004)
LQTS9 3p25 CAV3 Caveolin-3* INa % (Vatta et al. 2006)
LQTS10 11q23 SCN4B Nav1.5 "4* INa % (Medeiros-Domingo et
al. 2007)
JLNS1 11p15.5 KCNQ1 Kv7.1 # IKs$& (Tyson et al. 1997)
JLNS2 21q22.1 KCNE1 minK " IKs$& (Tyson et al. 1997)
LQTS1-10 refer to autosomal dominant Romano-Ward syndrome, JLNS1-2 refer to autosomal recessive Jervell-
Lange-Nielsen syndrome. * refer to ion channel-associated proteins, & refers to loss-of-function defect, % refers to
gain-of-function defect. Modified from (Lehnart et al. 2007).
3.3   Genotype-phenotype relationships
LQTS1
LQTS1 is caused by mutations in the KQT-like voltage-gated potassium channel-1 gene (KCNQ1) that
encodes the #-subunit of the slow component of the delayed rectifier IK current (IKs) (Roden et al. 2002).
KCNQ1 mutations have multiple consequences at the cellular level, all of them ultimately leading to a
loss-of-function defect (Wang et al. 1996). KCNQ1 proteins form functional channels as homotetramers
that co-assemble with minK, the "-subunit of the IKs current, in which defects are responsible for the
LQTS5 subtype (Splawski et al. 1997). LQTS1 is the most prevalent form of LQTS, accounting for up to
40-50% of the genotyped patients (Splawski et al. 2000, Tester et al. 2005b). Typically, KCNQ1 mutation
carriers present broad-based T waves on ECG (Moss et al. 1995), and the arrhythmias are triggered by
physical exercise, especially swimming (Schwartz et al. 2001).
LQTS2
LQTS2 results from loss-of-function mutations of the human ether-a-go-go-related (KCNH2/HERG) gene,
which codes for the #-subunit of the rapid delayed rectifier IK channel (IKr) (Curran et al. 1995). Most QT
prolonging agents block the IKr current in the cardiomyocyte, thus linking acquired LQTS with LQTS2
19
(Sanguinetti et al. 1995). This had led to the usage of HERG as a major target of drug safety, as
pharmaceutical companies test the developmental agents for direct blockage of the HERG channel.
Similarly to the IKs current in LQTS1 and LQTS5, the IKr current requires an assembly of KCNH2
homotetramers and MiRP proteins (Roden et al. 2002). LQT2 is estimated to constitute 35-40% of
clinical LQTS samples (Splawski et al. 2000, Tester et al. 2005b). Acoustic stimuli upon slow heart rate
induce arrhythmias among LQTS2 patients (Schwartz et al. 2001), and a characteristic ECG reveals a
low-amplitude T wave with notching (Moss et al. 1995).
LQTS3
LQTS3, the third most common cause of LQTS, arises from mutations in the SCN5A gene that encodes
the #-subunit of the cardiac sodium channel protein (Wang et al. 1995). These gene defects lead to an
abnormally persistent inward Na+-current (INa) (Wang et al. 1995), forming the initial upstroke of the
cardiac action potential. Recently, a mutation in the SCN4B gene coding for the "-subunit of the INa has
been identified as a putative LQTS susceptibility gene (Medeiros-Domingo et al. 2007). LQTS3 patients
have arrhythmias mainly while at rest, and the characteristic ECG phenotype includes peaked T waves
(Moss et al. 1995).
3.4   Risk stratification
Studies based on international samples postulate that 13% of untreated LQTS patients undergo cardiac
arrest or sudden cardiac death (Priori et al. 2003). The interplay between genetic defect, QTc duration,
and gender has been proposed to provide an algorithm for risk stratification (Priori et al. 2003). The
length of the QTc interval is the most valuable predictor of risk for cardiac events (Moss et al. 1991), and
a QTc exceeding 500 ms is associated with an increased risk of symptoms by the age of 40 years,
particularly in LQTS1 and LQTS2 (Priori et al. 2003). Since QTc interval duration is a dynamic measure,
incorporation of follow-up ECG recordings into LQTS risk assessment has been suggested (Goldenberg
et al. 2006).
LQTS patients resuscitated from cardiac arrest have a high relative risk of 12.9 of experiencing another
event (Moss et al. 2000), but the risk is not directly applicable to affected family members (Zipes et al.
2006). The time-dependent history of syncope has proven to be a valuable predictor of life-threatening
cardiac events among LQTS patients (Goldenberg et al. 2008a). Two or more syncopal episodes in the
last two years has resulted in a 18-fold risk increase among LQTS adolescents (10-20 years) (Hobbs et al.
2006), while recent syncope resulted in a 10-fold increased risk among adults (18-40 years) (Sauer et al.
2007). After the age of 40, time-dependent syncope in addition to female gender and LQTS3 genotype
remain independent risk factors for cardiac arrest/death (Goldenberg et al. 2008b).
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Studies based on an International Registry for LQTS reveal that patients with LQTS1 are less likely to
experience cardiac events than LQTS2 and LQTS3 patients (Priori et al. 2003). However, an earlier study
by Zareba et al. reported a higher risk for cardiac events in LQTS1 and LQTS2 than in LQTS3, although
lethality of these events was higher among LQTS3 patients (Zareba et al. 1998). Gender influences the
probability of cardiac events. Before the age of 15, male gender is associated with a 72-85% increased
risk for cardiac events in LQTS, but the gender risk is reversed in mid-adolescence (Locati et al. 1998). In
general, female LQTS2 patients have a worse prognosis, whereas male gender is associated with an
increased risk of cardiac events among LQTS3 patients (Priori et al. 2003). Mutational loci may play a
role in the risk stratification of LQTS patients since mutations in the pore region of the KCNH2 gene are
associated with an increased risk of cardiac events as compared with nonpore region gene mutations
(Moss et al. 2002). In addition, specific mutations, such as the KCNQ1 A341V mutation, have been
shown to result in an unusually severe clinical phenotype independently of the ethnicity of the LQTS
family (Crotti et al. 2007).
A simplified LQTS risk stratification scheme suggests categorization of LQTS patients into high-,
intermediate-, and low-risk subgroups (Moss et al. 2000, Goldenberg et al. 2008a). Secondary prevention
included patients with post-CPR and spontaneous TdP and a very high (14%) 5-year Kaplan-Meier
estimate for aborted cardiac arrest or sudden cardiac death, while high-risk subjects featuring either
prolonged QTc >500 ms or prior syncope had a 3% risk for cardiac arrest or sudden death. Low-risk
LQTS patients with QTc <500 ms and no syncopal episodes feature a 0.5% 5-year Kaplan-Meier estimate
for severe cardiac events. The authors emphasize cautious interpretation of such simplified models in the
dynamic clinical settings of LQTS.
3.5   Clinical management of LQTS
Due to the lack of randomized trials, recommendations for LQTS management are based on expert
opinions. Such preventive measures as avoidance of QT-prolonging drugs, electrolyte disturbances, and
adrenergic stimuli are essential and apply to all LQTS patients (Zipes et al. 2006). Beta-antagonists are
the standard therapy for LQTS and recommended for those at increased risk of arrhythmias. In general,
LQTS1 patients show a favorable response to beta-blocker therapy, while protection is only partial for
LQTS2 and LQTS3 patients (Priori et al. 2004). Implantable cardioverter defibrillator (ICD) is
recommended as secondary prevention for those who have been resuscitated from cardiac arrest and for
those who remain symptomatic despite proper beta-blocker treatment (Zipes et al. 2006). Arrhythmias in
LQTS3 are often managed with ICD in the absence of proper antiarrhythmic medication (Zipes et al.
2006). Gene-specific LQTS therapies, such as potassium-channel activators, sodium channel blockers,
and protein-kinase inhibitors, may be of value in the future (Khan et al. 2004).
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3.6   Finnish LQTS
Owing to few initial inhabitants, national isolation, and population bottlenecks (Peltonen et al. 1999),
some LQTS mutations have enriched in the Finnish population. Apart from Finland, LQTS founder
mutations have been reported in Norway (Tranebjaerg et al. 1999) and later in South Africa (Brink et al.
2005). Fodstad et al. demonstrated that four potassium channel mutations, KCNQ1 G589D (Piippo et al.
2001), KCNQ1 IVS7-2A>G, KCNH2 L552S, and KCNH2 R176W (Laitinen et al. 2000), account for 70%
of the known genetic spectrum of LQTS in Finland (Fodstad et al. 2004). Thus far, KCNQ1 G589D has
been identified in 650 Finnish individuals from over 90 families presenting clinical LQTS, while the other
three LQTS founder mutations have each been detected in 100-120 patients and 20 families (Swan et al.,
unpublished data).
In clinical samples, approximately 23-38% of the founder mutation carriers are symptomatic, and feature
a mean QTc of 459-470 ms (Fodstad et al. 2004). KCNH2 R176W, although reportedly present in 0.9% of
the apparently healthy blood donors, shows significant 8% enrichment among LQTS patients (Fodstad et
al. 2004). In addition, KCNH2 R176W was identified in six KCNQ1 G589D founder mutation carriers in
six LQTS families (Fodstad et al. 2006). These compound founder mutation carriers had a mean QTc of
473 ± 30 ms, as opposed to the QTc of 457 ± 33 ms in KCNQ1 G589D carriers (n=371) alone (Fodstad et
al. 2006). The compound carriers of the two founder mutations also featured a high (67%, 4/6) frequency
of symptoms (Fodstad et al. 2006). However, the role of KCNH2 R176W as a disease-causing mutation
has been questioned since it has been reported elsewhere as an innocent polymorphism (Ackerman et al.
2003, Mank-Seymour et al. 2006).
In vitro, KCNH2 R176W results in reduced current density and slight acceleration of the deactivation
kinetics (Fodstad et al. 2006). KCNQ1 G589D channels, when coexpressed with the minK in vitro, show
smaller currents and a rightward shift in the voltage of activation (Piippo et al. 2001). The intronic
KCNQ1 founder mutation shows a complete loss-of-function defect in vitro. Based on complete analysis
of the coding regions of the five most common genes responsible for LQTS1-3,5,6, LQT1 is the most
prevalent subtype (71%) in Finland, followed by LQT2 (23%) and LQT3 (6%) (Fodstad et al. 2004).
3.7   Genetic modifiers of LQTS
Considerable phenotypic variability occurs among the carriers of identical disease-causing LQTS
mutations. Reduced penetrance in LQTS was first reported by Vincent et al. in a large LQTS kindred
showing linkage to the KCNQ1 gene in chromosome 11 (Vincent et al. 1992). Later, South African family
members carrying KCNQ1 A341V were reported to have great variability in the QTc interval and in the
occurrence of symptoms (Brink et al. 2005). A number of mutation carriers showed QTc intervals within
the normal range (Brink et al. 2005), providing evidence of incomplete penetrance. Apparently, both
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genetic and environmental factors contribute to the reduced penetrance and variable expression of the
disease, and thus, to an individual’s risk for arrhythmias.
An estimated eleven million mutated single nucleotides, each with a >1% frequency, exist in the human
genome (Kruglyak et al. 2001). A majority of the polymorphisms are likely to be innocent variants, with
no pathophysiological consequences. However, several LQTS polymorphisms have been shown to affect
the expression, localization, and function of the mutant ion channels in in vitro experiments (Scicluna et
al. 2008). In addition, a number of LQTS polymorphisms are associated with a disease phenotype in vivo
(Scicluna et al. 2008) or, alternatively, with QT interval duration in the general population (Table 4).









KCNH2 K897T Oulu 187 % 0.005* (Pietila et al. 2002)
/HERG MONICA 1030 & 0.003 (Bezzina et al. 2003)
DESIR 398 & 0.0055 (Gouas et al. 2005)
KORA 3966 & 0.0006 (Pfeufer et al. 2005)
Framingham 2515 & 0.01 (Newton-Cheh et al. 2007)
FINCAVAS 1975 % 0.011* (Koskela et al. 2008)
Young Finns 1894 ) NS (Raitakari et al. 2009)
KCNH2 rs3807375 Framingham 2123 % 0.00006 (Newton-Cheh et al. 2007)
SCN5A H558R Twins 282 & 0.03 (Aydin et al. 2005)
DESIR 398 % 0.0063 (Gouas et al. 2005)
KCNE1 G38S Twins 282 ) NS (Aydin et al. 2005)
KORA S4 3966 ) NS (Akyol et al. 2007)
D85N Twins 282 ) NS (Aydin et al. 2005)
DESIR 398 % 0.02 (Gouas et al. 2005)
KCNE2 T8A Twins 282 % 0.009 (Aydin et al. 2005)
NOS1AP rs10494366 KORA S4 3966 % 1x10-7 (Arking et al. 2006)
Framingham 1805 % 0.004 (Arking et al. 2006)
KORA S3 2646 % 1x10-11 (Arking et al. 2006)
Rotterdam 5374 % 8x10-20 (Aarnoudse et al. 2007)
Amish 763 % 0.006 (Post et al. 2007)
Diabetes Heart 624 % 6x10-6 (Lehtinen et al. 2008)
Young Finns 1842 % <0.0001 (Raitakari et al. 2009)
GRAPHIC 1837 % 8x10-7/0.07§ (Tobin et al. 2008)
FINCAVAS 1924 % 0.006/0.02§ (Tobin et al. 2008)
rs16847548 DHS 3072 % 0.005-4x10-5 (Arking et al. 2009)
rs16856785 DHS 3072 % 0.01 (Arking et al. 2009)
* difference detected only in women. § in women/men, respectively.
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KCNH2/HERG polymorphisms
The very first report of genetic modifiers in LQTS involved the KCNH2 K897T polymorphism, which
was shown to shorten the QT interval among female LQTS1 patients (Laitinen et al. 2000). The variant is
relatively common, with a minor T allele frequency of 16% (Laitinen et al. 2000). Later, the same variant
was proposed to promote the expression of a disease phenotype in a family with KCNH2 A1116V
mutation (Crotti et al. 2005). Discrepant results have been observed among the numerous in vitro
electrophysiological experiments concerning the functional consequences of KCNH2 K897T
polymorphisms. K897T coexpression exaggerated the IKr reduction of the KCNH2 A1116V mutation,
corresponding to symptomatic compound carriers of the T897 allele and the mutation in the studied
family (Crotti et al. 2005). In addition, the T897 allele has been shown to exhibit changes in channel
expression (Paavonen et al. 2003), activation (Bezzina et al. 2003, Anson et al. 2004), deactivation
(Bezzina et al. 2003, Paavonen et al. 2003), and inactivation kinetics (Paavonen et al. 2003, Anson et al.
2004), along with alterations in current density (Bezzina et al. 2003, Paavonen et al. 2003, Anson et al.
2004). During the last few years, several population-based surveys have identified the T897 allele to be
associated with mild to moderate shortening of the QT interval, with a varying degree of statistical
significance (Table 4) (Bezzina et al. 2003, Gouas et al. 2005, Pfeufer et al. 2005, Newton-Cheh et al.
2007). An opposite QT-prolonging effect of KCNH2 K897T was reported in a small study of middle-aged
Finnish women (Pietila et al. 2002) and later in a larger sample size from the FINCAVAS study (Koskela
et al. 2008). No QT altering effect of the variant was observed in a study comprising young healthy Finns
aged 24-39 years (Raitakari et al. 2009).
In addition to KCNH2 K897T, a KCNH2 R1047L (Larsen et al. 2001) variant has been reported to be
associated with acquired LQTS (Sun et al. 2004, Mank-Seymour et al. 2006) and to alter the function of
the IKr channel in vitro (Sun et al. 2004). Recently, genome-wide association studies have recognized
intronic KCNH2 variation rs3807375 in association with QT interval prolongation (Newton-Cheh et al.
2007).
SCN5A variations
SCN5A H558R (Iwasa et al. 2000) was first reported among Japanese LQTS patients. Afterwards, a study
demonstrated the in vitro mitigating effect of the R558 allele on defective Na+ channel function in a
conduction disease phenotype caused by the SCN5A T512I mutation (Viswanathan et al. 2003). Moreover,
the variant has been shown to restore intracellular trafficking of the SCN5A mutations underlying LQTS3
(Ye et al. 2003) and Brugada syndrome (Poelzing et al. 2006). The effect of the H558R variant on QTc
interval duration was investigated by Gouas et al, who reported enrichment of the R558 allele among
individuals with longer QTc interval (Gouas et al. 2005). Aydin et al. showed shorter QTc intervals
among heterozygous carriers of the H558R variant (Aydin et al. 2005). The SCN5A S1102Y variant,
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which occurs with a 13% frequency in African Americans but not in Caucasians, is associated with an
increased risk for arrhythmias (Splawski et al. 2002, Burke et al. 2005) and sudden infant death syndrome
(Plant et al. 2006).
KCNE1 D85N
Substantial evidence suggests that KCNE1 D85N (Paulussen et al. 2004) may play a role as a modulator
of cardiac repolarization, as it seems to cluster among both acquired LQTS patients (Wei et al. 1999b,
Paulussen et al. 2004) and clinical LQTS patients with unidentified disease-causing mutation (Salisbury
et al. 2006). Westenskow et al. describe a putative QT-prolonging effect of the N85 allele in 13 clinical
LQTS1-2 patients (Westenskow et al. 2004). Further evidence was provided by Gouas et al. who reported
increased occurrence of the variant among 200 study subjects with the longest QTc interval as compared
with the 200 individuals with shortest QTc intervals in a French community-based study (Gouas et al.
2005). In addition, D85N has been shown to reduce the IKs current in vitro (Westenskow et al. 2004).
NOS1AP variants
Very recently, a genome-wide association study identified a novel NOS1AP gene as a modulator of
cardiac repolarization (Arking et al. 2006). Several common NOS1AP variants with a minor allele
frequency of 30-40% have been associated with mild to moderate QT prolongation in a total of nine
independent population-based surveys with convincing statistical support (Arking et al. 2006, Aarnoudse
et al. 2007, Post et al. 2007, Tobin et al. 2008, Arking et al. 2009, Raitakari et al. 2009). The NOS1AP
gene encodes a regulator of neuronal nitric oxide synthase, and hypothetical molecular mechanism
involves regulation of intra-cardiac signaling rather than a direct action on ion channel function (Arking
et al. 2006).
3.8   Acquired LQTS
In addition to congenital LQTS, LQTS may also manifest as a result of extrinsic factors such as QT-
prolonging medication, i.e. antiarrhythmics, antihistamines, and antipsychotics, and ischemic or structural
heart disease (Roden 2004), and is therefore classified as acquired LQTS (aLQTS). Female gender,
baseline QT prolongation, subclinical LQTS, electrolyte disturbances such as hypokalemia and
hypomagnesemia, concomitant structural or ischemic heart diseases, and congestive heart failure, are
known risk factors for aLQTS (Roden 2004). Drug-induced torsades de pointes (TdP) is clinically a
highly relevant form of aLQTS. An estimated 1-8% of patients receiving QT-prolonging medication show
QT prolongation or develop TdP (Viskin 1999). The onset of an arrhythmia is attributable to multiple hit
theory (Roden 1998); the reduced repolarization reserve (Roden 2006) is further challenged by extrinsic
factors resulting in electric disturbances of the heart. Owing to the similarities between congenital and
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acquired LQTS, genetic susceptibility to aLQTS is anticipated. In fact, a proportion of acquired LQTS
patients may present subclinical forme fruste congenital LQTS that will develop the disease phenotype
only in the presence of extrinsic stimuli. However, a surprisingly low yield (3-6%) of disease-causing
LQTS mutations have been identified in studies on aLQTS patients (Chevalier et al. 2001, Yang et al.
2002, Paulussen et al. 2004).
4   BRUGADA SYNDROME
4.1  Clinical characteristics of Brugada syndrome
Brugada syndrome was first described in 1992 as an arrhythmic disorder manifesting as elevated ST
segments on the right precordial leads, right bundle branch block, and risk for ventricular fibrillation and
sudden death (Brugada et al. 1992). The estimated prevalence is relatively high in Asian populations
(>1/1 000) (Miyasaka et al. 2001), but significantly lower in Caucasians (Hermida et al. 2000). Noticeable
ambiguity may underlie the prevalence calculations, as it is currently unknown whether a Brugada type
ECG alone stands for the disease phenotype. Three forms of Brugada ECGs exist, the type 1 ECG
patterns entitling a definitive diagnosis of Brugada syndrome if arrhythmias or positive family history are
present (Wilde et al. 2002). If the typical ECG characteristics are not apparent, sodium channel blockers
are used to augment the dysfunction of the mutated channel and unmask the concealed Brugada ECG.
Analogously to LQTS3, ventricular arrhythmias in Brugada syndrome occur while at rest or asleep
(Benito et al. 2008). Furthermore, male sex appears to be associated with increased risk for arrhythmias in
Brugada syndrome (Gehi et al. 2006). ICD is thus far the only proven effective treatment in the disorder
(Benito et al. 2008).
4.2  Molecular genetics of Brugada syndrome
Loss-of-function mutations in the #-subunit of the cardiac sodium channel encoded by the SCN5A gene
constitute the best-characterized cause of Brugada syndrome (Chen et al. 1998). To date, over a hundred
SCN5A mutations have been described to underlie the disorder (Antzelevitch 2007). However, only 18-
30% of Brugada syndrome patients carry identifiable mutations in the SCN5A gene (Antzelevitch et al.
2005), suggesting noncoding mutations or genetic heterogeneity in the disease pathogenesis. In fact, a
mutation in the GPD1-L gene encoding for glycerol-3-phosphate-dehydrogenase 1-like protein has been
reported to be cosegregated with the Brugada phenotype in a large kindred (London et al. 2007). The
GPD1-L mutation results in weaker cardiac sodium current owing to reduced cell surface expression of
the sodium channels in vitro (London et al. 2007).
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5   CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA
5.1   Clinical characteristics of CPVT
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe inherited arrhythmia disorder
that presents with stress-induced polymorphic ventricular tachycardia in structurally normal heart. A full
clinical description of the entity was provided by Leenhardt et al., who described 21 children with
physical or emotional stress-induced ventricular tachyarrhythmia (Leenhardt et al. 1995). The
arrhythmias appeared beyond a threshold heart rate, first as isolated monomorphic ventricular premature
complexes (VPCs), and later, as heart rate increased, they developed through bigeminia to bursts of
bidirectional or polymorphic ventricular tachycardia. The arrhythmias disappeared in reverse order as the
triggering catecholamines or isoproterenol infusion were eliminated. In these patients, the typical
symptoms included faintness, dizziness, visual disorders, and episodes of hypotonia, as well as
convulsive movements and loss of consciousness in more severe attacks. Due to resemblance to ictal
episodes, many of these children were initially misdiagnosed as having epilepsy. The mean age at onset
was 7.8 years, and the symptoms never presented before the age of 3 years. A family history of syncope
or sudden death was evident in 30% of patients.
Although no abnormalities are detectable in baseline ECG in typical CPVT, a few groups have reported
bradycardia among CPVT patients (Leenhardt et al. 1995, Postma et al. 2005) similarly to the earlier
findings of Leenhardt et al. (Leenhardt et al. 1995). In addition, variations in the length of the QTc
interval (Swan et al. 1999a, Choi et al. 2004) have been observed. As arrhythmias only occur in the
presence of catecholamines in classical CPVT, an exercise stress test is the standard diagnostic tool in
unmasking the arrhythmias. However, normal treadmill test results have also been reported in
symptomatic CPVT patients (Bauce et al. 2002, Priori et al. 2002a, Tester et al. 2005a). Indeed, a study
by Krahn et al. suggests that epinephrine infusion may be more sensitive than exercise testing in
detecting VPCs (Krahn et al. 2005). Traditionally, CPVT is defined as an arrhythmic disorder of the
structurally normal heart. However, a number of reports have described minor structural abnormalities
among CPVT patients (Tiso et al. 2001, d'Amati et al. 2005). The phenotypic heterogeneity of RyR2-
linked disorders was further illustrated by a recent report by Bhuiyan et al, who describe two families
with atrial arrhythmias, conduction defects and left ventricular dilatation and dysfunction due to a large
genomic RyR2 in-frame deletion (Bhuiyan et al. 2007b).
Onset of the disorder is typically in early adolescence, varying from two years (Priori et al. 2002c) to the
early forties (Swan et al. 1999a), and some evidence indicates that early onset may lead to a more severe
form of CPVT (Leenhardt et al. 1995). In addition, male gender, history of syncope, cardiac arrest, rapid
or sustained runs of VT are associated with an increased risk for major cardiac arrhythmias (Zipes et al.
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2006). A cumulative mortality rate of up to 30% has been reported by the age of 35 if CPVT is left
untreated (Swan et al. 1999a).
5.2   Molecular genetics of CPVT
CPVT1
The locus of familial polymorphic ventricular tachycardia was mapped to chromosome 1q42-43 in two
large Finnish families (Swan et al. 1999a), followed by studies leading to the identification of mutations
in the ryanodine receptor type 2 (RyR2) gene. The RyR2 functions as a calcium release channel on the
sarcoplasmic reticulum in cardiac myocytes. The first two reports described RyR2 mutations in families
affected by purely arrhythmogenic disorder (Laitinen et al. 2001, Priori et al. 2001), whereas Tiso et al.
also detailed minor structural abnormalities of the right and left ventricle in affected individuals (Tiso et
al. 2001), thus initially categorizing the disorder as ARVC/D type 2. Thus far, molecular genetic studies
have revealed over seventy RyR2 missense mutations clustering into three known ‘hotspot’ regions in the
RyR2 sequence: the N-terminus, the central region, and the C-terminal pore region. This is similar to the
mutations in RyR1 in malignant hyperthermia and central core disease (Marks et al. 2002). The functional
significance of the clustering of RyR2 mutations remains unclear, and no direct evidence exists of an
association between mutational loci and the phenotype (George et al. 2007). The clinical phenotypes of
reported RyR2 mutation carriers include patients with CPVT, and since the disorder is associated with
high mortality, also material from molecular autopsy (Tester et al. 2004). Approximately 40% of the
genotyped CPVT patients carry mutations in the RyR2 gene (Kontula et al. 2005).
CPVT2
In addition to the RyR2, CPVT has been linked to mutations in the CASQ2 gene, which encodes the Ca2+
binding storage protein calsequestrin in the sarcoplasmic reticulum. CASQ2 mutations cause an
autosomal recessive CPVT and was first described in a Bedoin kindred from northern Israel (Lahat et al.
2001a, Lahat et al. 2001b). Later, also heterozygous carriers of a CASQ2 mutation have been reported in
association with the disease phenotype (Postma et al. 2002, de la Fuente et al. 2008). The clinical
phenotype is identical to the RyR2-linked CPVT, but the CASQ2-associated recessive CPVT appears to
be related to earlier onset, higher average penetrance, and poorer prognosis than the dominant form of
CPVT1 (Lahat et al. 2001b, Postma et al. 2002).
Other putative disease-causing genes
CPVT presumably features genetic heterogeneity similar to that recognized among other ion
channelopathies. Not only genes affecting cardiac Ca2+ signaling, but also genes traditionally associated
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with LQTS have been linked to exercise-induced ventricular arrhythmias. Several groups have reported
KCNJ2 gene mutations underlying exercise-induced VPCs in the absence of Andersen syndrome (Tester
et al. 2006, Eckhardt et al. 2007, Ruan et al. 2007). In addition, mutations in KCNE1 underlying LQTS5
and ankyrin-B underlying LQTS4 have been reported to result in exercise-induced polymorphic
ventricular tachycardia (Mohler et al. 2004, Tester et al. 2006). A recent report by Bhuiyan et al. describe
a new locus 7p14-p22 for early onset autosomal recessive CPVT (Bhuiyan et al. 2007a). The candidate
genes located in the region include several genes expressed in the myocardium, and identification of the
mutation in the future is likely to expand the known genetic spectrum of CPVT.
5.3   Molecular mechanisms underlying CPVT
The cardiac-specific ryanodine receptor type 2 (RyR2) is a 2200-kDa tetramer located on the
sarcoplasmic reticulum of the cardiac myocyte (Figure 3). The cytosolic N-terminus interacts with
several regulatory proteins, such as calmodulin, calstabin, and sorcin, creating the RyR2 macromolecular
complex (Zalk et al. 2007). In addition, the RyR2 receptor complex is also modulated by the luminal
CASQ2 and the associated triadin and junctin (Gyorke et al. 2008). RyR2 channels are triggered by
cytosolic calcium, which enters the cell following an action potential–mediated opening of the L-type
calcium channels (Roden et al. 2002). Activated RyR2 channels release Ca2+ from the sarcoplasmic
















Figure 3. Cardiac calcium signaling and regulation of RyR2 channel function. L=L-type Ca2+ channel,
SR=sarcoplasmic reticulum, FKBP12.6= calstabin, TRD=triadin, JCN=junctin, SERCA2a=sarcoplasmic reticulum
Ca2+ ATPase, NCX=Na+/Ca2+ exchanger.
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The work by Lehnart et al. described the functional consequences of three RyR2 mutations (P2328S,
Q4201R, V4653F) originally identified in Finnish CPVT patients (Lehnart et al. 2004). Depletion of
calstabin from the RyR2 receptor complex under PKA hyperphosphorylation was postulated to cause
leaky RyR2 channels, and thus, delayed afterdepolarization and arrhythmias (Lehnart et al. 2004).
Analogously, calstabin-deficient mice featured polymorphic VT in an exercise stress test (Wehrens et al.
2003). The arrhythmias were prevented in calstabin2+/- mice, but not in calstabin2-/- mice, by treatment
with JTV19 (K201, a 1,4-benzothiazepine) (Wehrens et al. 2004), a Ca2+ channel stabilizer demonstrated
to increase binding of calstabin to RyR2 (Lehnart et al. 2006). Furthermore, overexpression of FKBP12.6
in transgenic mice showed a marked increase in the binding of calstabin to RyR2 and prevented triggered
ventricular tachycardia by reducing diastolic sarcoplasmic Ca2+ leakage (Gellen et al. 2008). The theory
has thereafter been questioned by several groups that propose a calstabin-independent mechanism. Jiang
et al. first described several CPVT-linked RyR2 mutations that featured enhanced luminal sensitivity and
resulted in store overload-induced Ca2+ release (SOICR) (Jiang et al. 2002, George et al. 2003, Jiang et al.
2004, Jiang et al. 2005). Interestingly, an opposite direction of action has also been reported in a CPVT-
linked RyR2 mutation, resulting in a loss of luminal Ca2+ activation and SOICR (Jiang et al. 2007). In
addition, the role of PKA hyperphosphorylation in the CPVT pathogenesis has been called into question
(George et al. 2003, Xiao et al. 2004).
The generation of CPVT mouse models has provided valuable insights into disease mechanisms. CPVT-
linked transgenic mice, the RyR2 R4496C (Cerrone et al. 2005, Liu et al. 2006, Cerrone et al. 2007) and
RyR2 R176Q (Kannankeril et al. 2006) knock-in mouse, develop bidirectional ventricular arrhythmias in
response to adrenergic stimuli and show mild structural abnormalities in the latter, similarly to humans
carrying the corresponding RyR2 mutations. However, the interaction of calstabin with RyR2 in mutant
RyR2 R4496C+/- and R176Q+/- myocytes and the phosphorylation status were equivalent to those seen in
nonmutant mice (George et al. 2003, Kannankeril et al. 2006, Liu et al. 2006). In addition, K201 failed to
prevent ventricular arrhythmias in RyR2 R4496C+/- mice (Liu et al. 2006). Plausibly, the mutational loci
determine the properties of mutant RyR2 channels that ultimately lead to an enhanced sarcoplasmic Ca2+
leak, and thus, to the DADs and induction of arrhythmias in CPVT. A study on RyR2 R2474S+/- mice
found leaky RyR2 channels in the brain to cause seizures independently of cardiac arrhythmias,
suggesting combined neurocardiac nature of CPVT (Lehnart et al. 2008).
To date, seven mutations in the CASQ2 gene have been linked to the CPVT2 phenotype. The proposed
mechanisms involve alterations in the CASQ2 binding and buffering properties (Kim et al. 2007) and
disrupted interaction of CASQ2 with the RyR2 receptor complex (Terentyev et al. 2006). Impaired
CASQ2 buffering capacity is proposed to lead to altered sarcoplasmic free Ca2+ content, which is
sensored by the RyR2 receptor (Gyorke et al. 2008). These mechanisms are likely to act in parallel in in
vivo arrhythmogenesis (Gyorke et al. 2008). In murine studies, the CASQ2-null mice showed normal
sarcoplasmic Ca2+ release and contractile function, but once exposed to catecholamines, the CASQ2-null
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cardiomyocytes displayed an increased diastolic Ca2+ leak from the sarcoplasmic reticulum, thus
contributing to catecholaminergic ventricular arrhythmias (Knollmann et al. 2006). Furthermore, a report
of both CASQ-/- and CASQ307/307 mice revealed adaptive changes in CASQ2 deficiency and stress-
augmented RyR2 leakiness (Song et al. 2007).
5.4   Clinical management of CPVT
The standard treatment of CPVT is beta-antagonists at the maximal tolerated dose (Zipes et al. 2006).
According to the Task Force on SCD in 2006 (Zipes et al. 2006), silent carriers of a RyR2 mutation
should also be treated. Although some prognostic risk factors exist for malignant arrhythmias, such as
male gender and early onset, ICD is generally recommended in the secondary prevention of cardiac arrest
and for patients who remain symptomatic despite maximal beta-blocker treatment. All patients with overt
CPVT should avoid excess adrenergic stimuli such as strenuous exercise and swimming.
However, the efficacy of beta-blockers is not complete. Priori et al. treated RyR2-genotyped CPVT
patients with nadolol, metoprolol, or propranolol, but 7 of 19 patients (37%) remained symptomatic
(Priori et al. 2002c). Similar results were achieved in nongenotyped CPVT patients by Sumitomo et al.
(Sumitomo et al. 2003). Bauce et al. (Bauce et al. 2002) and Postma et al. (Postma et al. 2005) treated 17
and 50 patients, respectively, one of whom had a fatal outcome due to noncompliance with treatment. In
the Finnish patient population, three of the 39 genotyped CPVT patients died due to poor adherence to
drug treatment (Swan et al., unpublished data). Considering the incomplete protection of beta-blockers in
preventing sustained VTs in CPVT, better agents for clinical management of the disorder are being
sought. Swan et al. found calcium channel antagonism to reduce the number of exercise-induced VPCs
by 76% (Swan et al. 2005). Recently, Rosso et al. showed similar results following oral administration of
combined beta-blocker-verapamil therapy (Rosso et al. 2007). In addition, experimental agents
K201/JTV519 have undergone rigorous investigations and may add to the medical arsenal in the future
(Wehrens et al. 2004, Wehrens et al. 2005). A recent report describes a successful surgical left cardiac
sympathetic denervation of three CPVT patients (Wilde et al. 2008). The researchers propose that the
procedure may offer an effective alternative treatment to CPVT patients who remain symptomatic with
beta-blockers (Wilde et al. 2008).
6   SUDDEN CARDIAC DEATH
Sudden cardiac death (SCD) is defined as an unexpected death occurring shortly (<1 hour) after the onset
of a change in clinical status (Zipes et al. 2006). Each year SCD claims over 300 000 lives in the United
States alone (Zheng et al. 2001). The majority of SCDs occur due to complications of coronary artery
disease (Virmani et al. 2001), and hence, conventional cardiovascular risk factors, such as high systolic
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blood pressure, smoking, diabetes, and left ventricular hypertrophy, have proven to be potent
independent risk factors of SCD at the population level (Cupples et al. 1992, Jouven et al. 1999). Only
5% of the victims of SCD are estimated to have a primary electric disorder of the heart (Zipes 2005).
First-degree relatives of SCD victims have an increased risk of sudden death, suggesting that hereditary
factors contribute to an individual’s risk for SCD (Jouven et al. 1999, Friedlander et al. 2002, Kaikkonen
et al. 2006). Pathogenic gene variants causing familial arrhythmia disorders and/or structural heart
disease are powerful predictors of SCD in a family (Priori et al. 2003). Since these disease-causing gene
mutations are extremely rare in the general population, they cannot predict the risk of SCD in the
background population. Previously, the common SCN5A S1102Y variant, unidentifiable in Caucasians,
was shown to be associated with an increased risk of arrhythmias and sudden death among African
Americans (Splawski et al. 2002, Plant et al. 2006), thus far being the only described ion channel gene
variant with direct implications for major cardiac events at the population level. Further knowledge of
population-level genetic contributors of SCD could improve management of inherited arrhythmia
disorders, and, ultimately, risk stratification of the general population.
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AIMS OF THE STUDY
The aim of the study was to identify common and rare ion channel gene variants underlying severe
ventricular arrhythmias in clinical samples and in the general Finnish population. Specific aims were as
follows:
1. To investigate the role of the four Finnish LQTS founder mutations underlying drug-
induced acquired LQTS (I).
2. To estimate the prevalence of the four Finnish LQTS founder mutations in the Finnish
population and to examine their effect on the QT interval at the population level (II).
3. To evaluate the effect of common gene variants on QT interval duration in the Finnish
background population (III).
4. To investigate RyR2 involvement in typical and atypical CPVT and sudden cardiac death
(IV, V).
5. To identify disease-causing SCN5A mutations underlying Brugada syndrome in the
Finnish patient population (unpublished data).
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MATERIALS AND METHODS
1   STUDY SUBJECTS
In Study I, the sample consisted of 16 patients with antiarrhythmic drug–associated torsades de pointes
arrhythmia referred to the Laboratory of Molecular Medicine, University of Helsinki, for testing of ion
channel gene defects. In Studies II and III, the population was built on a two-stage stratified cluster
sample of 8028 individuals from the Health 2000 Survey. The participants were compiled in September
2000 – June 2001 and represented the entire Finnish population aged '30 years (Aromaa 2004). DNA
samples were available from 6334 individuals and digitized 12-lead ECG were recorded from 6295 study
participants. Jointly, DNA samples and legible ECGs were available from 6027 individuals. A total of
959 subjects were excluded from statistical analyses due to complete left or right bundle branch block,
QRS ' 120 ms, atrial fibrillation or flutter, pacemaker, or usage of medications affecting the QT interval.
In Study III, the 27 carriers of the Finnish LQTS founder mutations were also excluded from the final
analyses. In secondary analyses of Study III, individuals older than 60 years, with QTc ' 500 ms, history
of myocardial infarction, and heart failure were eliminated.
Study IV consisted of 19 victims of sudden cardiac death referred to the Laboratory of Molecular
Medicine, University of Helsinki, for genetic testing. A total of 300 ethnically matched blood donors
were used as controls in determining the frequency of identified gene variants in the Finnish background
population. The relatives of the deceased individuals were tested (n=64) for the identified mutations, and
mutation carriers (n=20) were further clinically evaluated. Study V included 33 patients referred to the
Laboratory of Molecular Medicine due to frequent ventricular ectopy of unknown origin. Altogether 232
relatives underwent cardiac examination. The occurrence of SCN5A mutations was investigated in six
index patients referred to the Laboratory of Molecular Medicine because of syncopal spells and ECG
patterns resembling Brugada syndrome (unpublished data). Written consent was obtained from all
patients, and the Ethics Committee of the Department approved the studies.
2   CLINICAL EVALUATION
In Study I, the clinical records of each patient were systematically analyzed to collect data of the clinical
circumstances leading to the diagnosed proarrhythmia. Resting ECGs, cardiac ultrasonography, and
laboratory test results were collected before and after the documented episode of TdP. Moreover,
concurrent medications were carefully evaluated to detect potential drug interactions. In Studies II and III,
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clinical data were based on the patient’s health questionnaire, ECG measurements, and physician’s
clinical examination. The mutation carriers in Study IV underwent a thorough clinical examination
comprising a health inquiry, resting ECG, cardiac ultrasonography, 24-hour ambulatory ECG recording,
maximal exercise stress test, and gradual intravenous epinephrine infusion 0.05 µg/kg/min-0.4 µg/kg/min
for up to 20 min. The same protocol, except for the epinephrine test, was applied to participants in Study
V. In the unpublished study of Brugada syndrome, relatives underwent exposition to intravenous
flecainide (2 mg/kg for 30 min) if Brugada alterations were not apparent in baseline ECG.
QT intervals were determined from the onset of the QRS to the intersection of the T wave tangent to the
baseline. Manual QT interval measurements on lead II were performed in Studies I, II, IV, and V. In
Studies II and III, QT parameters from a 12-lead digitized ECG were measured based on a previously
described algorithm (Oikarinen et al. 1998) and mean QT interval was used for final analyses. QT
intervals were corrected for heart rate (QTc) utilizing Bazett’s formula (Bazett 1920) (Studies I, II, IV, V).
In Study III, QT intervals were heart rate-corrected with the nomogram (Karjalainen et al. 1994) derived
from the same study population.
3   MOLECULAR GENETIC STUDIES
3.1   DNA extraction and polymerase chain reaction (I-V)
DNAs were derived from peripheral blood lymphocytes and extracted with either a standard phenol
chloroform method (Blin et al. 1976) or a salting-out method with the Puregene DNA whole-blood
purification kit (Gentra, Minneapolis, MN, USA). Amplification of genomic DNA was accomplished
with polymerase chain reaction (PCR) (Mullis et al. 1986) utilizing Amplitaq Gold DNA polymerase
(Applied Biosystems, Foster City, CA, USA) and intronic primers in screening for novel mutations.
3.2   Screening for novel mutations (IV,V)
Novel mutations in the RyR2 (NM_001035), FKBP1B (NM_004116), ATP2A2 (NM_170665), SLC8A1
(NM_021097), and SCN5A (NM_198056) genes were detected by direct sequencing. Sequencing of the
CASQ2, the integral Ca2+ storage protein, was excluded from Study V since the mode of inheritance in the
study material did not support autosomal recessive inheritance and a previous study has failed to detect
causative CASQ2 mutations underlying CPVT in Finnish patients (Laitinen et al. 2003). Amplified DNA
regions were purified using shrimp alkaline phosphatase and exonuclease 1, and sequencing reactions
were completed with BigDye reagents (Applied Biosystems, Foster City, CA, USA). Automated
sequencer ABI 3730 (Applied Biosystems) separated the reactions based on the incorporated di-
35
deoxynucleotides that terminate the elongation reaction (Sanger et al. 1977). Sequences were analyzed
with Sequencer software 4.5 (Gene Codes, Ann Arbor, MI, USA).
3.3   Detection of known DNA alterations (I-V)
Detection of the known genetic alterations was performed by restriction enzyme analysis utilizing natural
enzyme-specific cleavage sites on genomic DNA followed by electrophoretic separation of the resulting
digestion products (Studies I, II and V, unpublished data). In Study IV, a modification of this method, i.e.
primer-induced restriction enzyme analysis (PIRA) (Kumar et al. 1989), was applied. Denaturing High-
Performance Liquid Chromatography (dHPLC) (Wave Nucleic Acid Fragment Analysis System HSM
3500, Transgenomic, Omaha, NE, USA) was utilized to detect of the frequency of allelic variants in
controls (Studies IV and V). The method is based on DNA heteroduplex formation and their separation
from homoduplexes in the Transgenomic cartridge. The temperature in the column was calculated by
using the Wavemaker 4.1 software (Transgenomic). PCR products showing a divergent chromatogram
profile were sequenced in the forward and reverse directions to confirm the nucleotide alteration.
The previously reported 1.1-kb RyR2 exon 3 deletion (Bhuiyan et al. 2007b) was investigated using
multiplex ligation-dependent probe amplification (MLPA) analysis of RyR2 exon 3 (Salsa MLPA Kit
P168, MRC Holland, Amsterdam, the Netherlands) and with PCR using primers located in introns 2 and 3
of the RyR2 gene (Study V). The MLPA method is designed to detect copy number changes and uses a
fluorescently labeled primer pair and multiple probes of different lengths (Schouten et al. 2002). The
amplicons of the ligated probes with a target sequence in the sample DNA are separated by capillary
electrophoresis, and the peak pattern is attributable to the relative quantity of the amplification product.
The detailed structure of the RyR2 exon 3 deletion was defined by direct sequencing.
High-throughput methods for detection of allelic variants were used in Studies II and III. The primary
method was Sequenom MALDI-TOF mass spectrometry (MassArray Compact Analyzer, Sequenom Inc.,
San Diego, CA, USA) (Storm et al. 2003), which utilizes primer extension reaction chemistry in genotype
characterization and allows multiplexing of SNPs to a single well. Homogenous MassEXTEND Assay is
based on annealing of the hME oligonucleotide primer adjacent to the SNP and resulting allele-specific 2-
3 base extension products with unique molecular masses. The more advanced iPLEXTM Assay allows
more efficient genotyping up to a 36-plex level and differs from the hME Assay in utilizing single-base
extension. Reactions for the MALDI-TOF assays were designed by utilizing Sequenom Assay Designer
3.1 software, and results were evaluated with SpectroAnalyzer 3.4 software. The SNP rs1805123 (Study
III) did not fit a multiplex assay and was therefore genotyped independently with Applied Biosystems
TagMan SNP Genotyping Assay C_11631103_10 (Applied Biosystems, Foster City, CA, USA). The
assay consists of two fluorescence-labeled detectors specific for the alleles at the SNP site. The allelic
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discrimination assay of the 7900HT Real Time PCR System (Applied Biosystems) measures the
fluorescence signals, and SDS2.2 software (Applied Biosystems) was used in the data analysis.
4 IN VITRO ELECTROPHYSIOLOGICAL STUDIES
RyR2 mutagenesis was accomplished with the QuikChange II XL mutagenesis kit (Stratagene, La Jolla,
CA, USA) on cassettes of hRyR2 subcloned into pBlueScript vector. HEK293 cells were co-transfected
with full-length hRyR2 in pCMV5 vector with pCMV5/FKBP12 using a calcium phosphate precipitation
technique. Microsomes containing recombinant RyR2 were phosphorylated with the protein kinase A
catalytic subunit, and phosphorylation status was confirmed in an immunoblot assay.
The single-channel recordings were conducted in planar lipid bilayers under voltage clamp conditions.
Microsomes containing the recombinant RyR2-channels were fused to the lipid bilayer consisting of 3:1
phosphatidyl ethanolamine and phosphatidyl serine (Avanti Polar Lipids, Alabaster, AL, USA) by
increasing the K+ ion gradient across the membrane. The cis solution consisted of 50 mM KCl, 250 mM
HEPES, 125 mM TRIS, 1 mM EGTA, and 0.5 mM CaCl2 and the symmetric trans solution of 50 mM
KCl, 53 mM Ba(OH)2, and 250 mM HEPES. All experiments were carried out in pH 7.35, and free Ca2+
concentration was determined using the program CHELATOR
(http://www.stanford.edu/~cpatton/maxc.html). Sequential addition of 20 mM CaCl2 to the cis side was
followed by 3 min of continuous recording of channel activity at each concentration. At the end of each
experiment, ryanodine (5 µM) was applied to confirm the channel identity. Data were collected using
AxoScope1 (Axon Instruments, Foster City, CA, USA) and analyzed by using the pClamp 6 program
(Axon Instruments). Statistical analysis was performed with Student’s t-test using Microcal™ Origin 6.0
software (OriginLab Corporation, Northampton, MA 01060, USA). A P-value of 0.05 was considered
statistically significant.
5   STATISTICAL ANALYSES
In Studies II and III, linear regression analysis was applied to assess the size effects of genetic variants to
age-, sex-, and heart rate-adjusted QT interval. The association was tested in both a one-degree (1df)
additive model and a two-degree freedom (2df) general test. The prevalence estimates with 95%
confidence intervals (Studies II and III) were derived from the weighted study population. Logistic
regression was used in Study III to determine the odds ratio for a prolonged QT interval per each quintile
increase in QT-prolonging score, which was determined by the effect of each QT-prolonging genotype
relative to the reference genotype. In Studies I, VI and V, the statistical analysis was accomplished by
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Student’s t-test for continuous variables and Chi-square (x2) and Fischer’s exact tests for dichotomous




1   LQTS FOUNDER MUTATIONS IN THE FINNISH POPULATION
1.1   LQTS founder mutations underlying acquired LQTS
In Study I, 16 consecutive unrelated cases of antiarrhythmic-induced torsades de pointes (TdP) patients
referred to the Laboratory of Molecular Medicine were screened for the four Finnish LQTS founder
mutations. In addition, the clinical conditions leading to acquired LQTS were evaluated, retrospectively.
The culprit drugs included amiodarone in seven, sotalol in six, flecainide in two, and propafenone in one
enrolled subject. In six patients, amiodarone was administered intravenously. The mean QTc (Bazett)
appeared markedly prolonged 470 ± 70 ms before drug administration and was 600 ± 70 ms at the time of
TdP. However, seven individuals (44%) had a QTc < 470 ms at baseline. In addition to the baseline QT
prolongation, the enrolled patients featured one or more known proarrhythmic risk factors (Roden 2004)
such as female gender (n=10), hypokalemia (n=13), administration of diuretics (n=8), and congestive
heart failure (n=5). Three patients (19%) carried one of the four LQTS founder mutations, which is
significantly more than in the Finnish background population (Study II, p=5.1x10-5). A KCNQ1 G589D
mutation was apparent in one amiodarone-induced TdP, while KCNQ1 G589D and KCNH2 L552S
underlied one case each initiated by sotalol. The mean baseline QTc of the mutation carriers was 480 ± 20
ms, and corresponding QTc at the time of proarrhythmia was 540 ± 40 ms. None of these three patients
reported a history of syncope before the drug challenge.
1.2   LQTS founder mutations in the Finnish background population
A large population-based cohort of 6334 Finnish individuals aged 30 or more was utilized in Study II to
estimate the actual prevalence of the four LQTS founder mutations in the Finnish background population.
Of the 6334 individuals genotyped over the course of the study, founder mutations were identified in 27;
KCNQ1 G589D in eight, KCNQ1 IVS7-2A>G in one, KCNH2 L552S in two, and KCNH2 R176W in 16
individuals. Collectively, these four LQTS founder mutations constitute a prevalence estimate of 0.4%
(95% CI 0.3-0.6%) in the Finnish population. As the original Health 2000 cohort was a cluster sample,
detailed maps of the origins of these founder mutations in the Health 2000 Study and in the clinical
samples were constructed to ascertain that the clinical LQTS families had not become overrepresented in
the Health 2000 study material (Study II, Supplementary data).
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To evaluate the QT-prolonging effect of these founder mutations, a total of 984 individuals were excluded
due to the extrinsic factors potentially affecting the length of QT interval or the accuracy of the QT
interval measurement technique. The mean QTc interval among founder mutation noncarriers was 396 ±
22 ms, while the founder mutation carriers had a QTc of 423 ± 30 ms (n=25, two founder mutation
carriers were excluded due to usage of potential QT-prolonging drugs, p=1.26x10-9). The KCNQ1 G589D
resulted in a mean QTc interval of 435 ± 40 ms, KCNH2 L552S 438 ± 26 ms, and KCNH2 R176W 430 ±
20 ms in the Finnish background population (Table 5). In linear regression analysis, the mean QT
intervals were adjusted for age, sex, and heart rate. The mutant allele A of KCNQ1 G589D was associated
with a 50.5-ms increase in the adjusted QT interval compared with mutation noncarriers (SE 7.1, 2.7 SD,
p=8.99x10-13). The minor KCNH2 R176W allele resulted in a 22.2-ms increase in the adjusted QT
interval compared with noncarriers (SE 4.7, 1.2 SD, p=2.15x10-6). Systematic ascertainment of
arrhythmias was not part of the Health 2000 Study. One mutation carrier of KCNQ1 G589D with a QTc
of 520 ms had previously been symptomatic.












4/3 1/1 8/8 2524/2234
Age, years 43 ± 7 (34-57) 38 ± 2 (36-39) 53 ± 11 (30-70) 51 ± 14 (30-97)
HR, bpm 55 ± 5 (48-63) 60 ± 16 (49-71) 61 ± 7 (50-72) 63 ± 11 (34-120)
QT, ms 451 ± 33 (406-507) 442 ± 32 (420-465) 414 ± 33 (357-480) 388 ± 30 (279-536)*
QTc, ms 435 ± 40 (403-520) 438 ± 26 (420-457) 430 ± 20 (396-459) 396 ± 22 (323-514)†
Data are presented as mean ± SD (range), unless otherwise indicated. HR=heart rate, bpm= beats per minute, QTc =
QT interval corrected for heart rate using Bazett’s formula. * refers to p=2.17x10-10 and † to p=1.26x10-9 in
comparison of QT parameters among founder mutation carriers and noncarriers. The excluded carrier of KCNQ1
G589D had a QTc of 438 ms and the carrier of KCNQ1 IVS7-2A>G a QTc of 409 ms. Because of failures in
genotyping the individual mutations, the genotype numbers do not add up to a total of 5068 individuals.
2   COMMON GENE VARIANTS MODIFY QT INTERVAL AT POPULATION LEVEL
In Study III, the population-based Health 2000 material was utilized to test the association of common
LQTS and NOS1AP gene variants with QT interval duration in the Finnish background population.
Nonsynonymous LQTS variants were selected if they were identifiable in the Finnish population based on
previous studies of clinical LQTS samples (Fodstad et al. 2004) and showed evidence of a functional role
in disease pathogenesis. In addition, recently characterized NOS1AP variants and an intronic KCNH2
variant with apparent QT-prolonging effects in other population samples were included in the study. The
results of linear regression analysis showing the effect of each SNP on age-, sex-, and heart rate (Nc) -
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adjusted QT interval are presented in Table 6. The KCNE1 D85N minor allele with a frequency of 1.4% is
associated with a 10.5-ms prolongation of the adjusted QT interval (SE 1.6, 0.57 SD, p=3.6x10-11).
Accordingly, the mean QTNc among major homozygotes was 393 ± 20 ms (n=4684), while the D85N
heterozygotes had a mean QTNc of 404 ± 20 ms (n=127) and minor allele homozygotes a mean QTNc of
415 ± 23 ms (n=3). In agreement with previous studies, the modest QT-prolonging effect of KCNH2
rs3807375 (effect size 1.6 ms, SE 0.4, p=5.4x10-5) and several correlated NOS1AP variants were
replicated in the Health 2000 material. The strongest NOS1AP association was observed with rs2880058,
with a 4.0-ms (SE 0.4) prolongation of the adjusted QTNc interval per each minor G allele (p=3.2x10-24).
The KCNH2 K897T variant showed a modest 2.6-ms shortening in adjusted QTNc interval per each minor
C allele (p=2.1x10-7).
Table 6. Effect of SNPs on age-, sex-, and heart rate (Nc) -adjusted QT interval in the Health 2000 Study.










KCNH2 rs3807375 2.1 (0.12) 2.9 (0.16) 1.4x10-4 0.004  1.6 (0.08) 4.7x10-5 0.004
KCNH2 K897T -2.6 (-0.14) -4.9 (-0.27) 1.4x10-6 0.006  -2.6 (-0.14) 2.1x10-7 0.006
KCNH2 R1047L -0.5 (-0.03) -10.8 (-0.58) 4.0x10-3 0.002  -1.5 (-0.08) 4.9x10-2 0.001
SCN5A R190G -0.5(-0.03) - 8.5x10-1 0.000  -0.5(-0.03) 8.5x10-1 0.000
SCN5A H558R 1.4 (0.08) 3.1 (0.17) 6.6x10-3 0.002  1.5 (0.08) 2.0x10-3 0.002
SCN5A A572D 0.3 (0.02) 7.1 (0.39) 7.2x10-1 0.000  0.5 (0.03) 6.6x10-1 0.000
KCNE1 D85N 10.5 (0.57) 20.6 (1.12) 3.1x10-10 0.009  10.5 (0.57) 3.6x10-11 0.009
KCNE1 G38S 0.6 (0.03) 0.7 (0.04) 5.1x10-1 0.000  0.4 (0.02) 2.9x10-1 0.000
KCNE2 T8A 0.1 (0.01) - 9.8x10-1 0.000  0.1 (0.01) 9.8x10-1 0.000
NOS1AP rs2880058 4.5 (0.24) 7.7 (0.41) 2.3x10-23 0.021  4.0 (0.22) 3.2x10-24 0.021
NOS1AP rs4657139 4.5 (0.24) 7.5 (0.41) 4.9x10-23 0.022  4.0 (0.22) 9.0x10-24 0.021
NOS1AP rs10918594 3.9 (0.21) 6.5 (0.35) 2.2x10-22 0.021  3.9 (0.21) 8.7x10-23 0.020
NOS1AP rs10494366 4.0 (0.22) 6.6 (0.36) 4.6x10-18 0.016  3.5 (0.19) 8.3x10-19 0.016
Values are differences from major homozygotes in milliseconds. Beta coefficients standardized to the SD of the
age-, sex-, and nomogram-adjusted residuals are shown in parentheses. The standard deviation of age-, sex-, and
nomogram-adjusted QT residuals is 18.39.
41
To assess the clinical impact of the four QT-modulating SNPs, KCNE1 D85N, KCNH2 rs3807375,
KCNH2 K897T, and a NOS1AP rs2880058, we composed a QT-prolonging score by using the beta
coefficients from the 2 df model as weights. The score calculates the predicted QT effect for each
individual based on their genotype. A score of 0 results for a study subject who carriers none of the alleles
associated with QT interval prolongation. A one-point increase in the QT-prolonging score was associated
with a 0.89-ms increase in the adjusted QTNc interval (p=4.6x10-38). We also divided the study material
into quintiles of a continuous QT-prolonging score and found a 2.4-ms increase in the age-, sex-, and
heart rate-adjusted QT interval for each quintile increase in score (p=1.6x10-32). The mean QTNc in the
first quintile was 388 ± 19 ms, while the mean QTNc in the fifth quintile was 398 ± 20 ms (p=8.3x10-23).
3 RYR2 MUTATIONS IN SUDDEN CARDIAC DEATH
Upon studying 19 consecutive cases of sudden cardiac death referred by Finnish forensic medicine
physicians to the Laboratory of Molecular Medicine for genetic analyses, two novel RyR2 missense
mutations were identified in direct sequencing of the coding regions of the gene. Neither of the mutations
were identifiable in 600 control alleles from randomly collected blood donors.
The RyR2 G2145R, located in the vicinity of the central mutational hot spot region, changes the polarity
and creates a positive charge. A victim of sudden cardiac death, aged 41 years, had experienced a
syncopal event related to exercise (Figure 4, Family A). The medicolegal autopsy provided no apparent
explanation for the sudden death. The 23-year-old daughter of the index patient carried the RyR2 mutation,
but did not feature abnormalities upon clinical examination. The in vitro analysis of the RyR2 G2145R in
single-channel recordings showed statistically significantly enhanced open probability to cytosolic Ca2+
under basal conditions at 1*M [Ca2+] compared with wild-type RyR2 channels (Figure 5). The PKA
phosphorylated RyR2 G2145R channels exhibited similar open probabilities to the phosphorylated wild-
type RyR2 channels.
The mutation RyR2 R3570W was identified independently in two victims of sudden death (Figure 4,
Families B, C). This mutation is located in exon 75 of the RyR2 gene, where disease-causing mutations
have not previously been identified. The index patient in Family B died suddenly at the age of 17 years
while playing volleyball, and the index patient in Family C at the age of 55. In both victims, medicolegal
autopsy revealed a moderately enlarged and dilated heart of over 500 g and a slightly hypertrophic (12-15
mm) left ventricular wall. Histology did not show myofibrillar disarray, and the main coronary arteries
were normal in both men.
In the RyR2 R3570W families, molecular genetic analyses were conducted on 64 family members, 20 of





* * * * * * * *













? ? ? ?














? ? ? ? ? ? ? ? ?




* * * *
*
*
* * * * *



























* * * *
?
?
?? ? ? ?
?




*C:IV:3 * C:IV:5 * C:IV:13





Figure 4. Pedigree data on families with RyR2 missense mutations (A-C, F-H), RyR2 exon 3 deletions (D,E), and
SCN5A mutations (I,J) (Studies IV and V, unpublished data). Family A=RyR2 G2145R, B and C=RyR2 R3570W, D
and E= RyR2 exon 3 deletion, F=RyR2 S616L, G=RyR2 R1051P, H=RyR2 N3308S, I=SCN5A E1784K, J=SCN5A
IVS21+16G>A.
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IVS74-3C>G unidentifiable in controls that resides in close proximity to the amino acid-altering mutation
in exon 75. A total of 17 RyR2 R3570W mutation carriers were available for further clinical examination.
None of the relatives reported syncopal events. Altogether, four carriers showed similar mild structural
changes of the left ventricle as the two deceased individuals (Table 7). Interestingly, ventricular
premature complexes (VPCs) occurring in resting conditions were evident in two living carriers. The 34-
year-old sister of the index patient in Family B featured recurrent VPCs at rest, which were largely
suppressed during exercise. Holter recording revealed over 5000 polymorphic VPCs and a salvo of three
beats. In vitro single-channel recordings showed a significant gain-of-function defect for the mutant
native RyR2 R3570W channels in the range of lower diastolic to upper systolic cytosolic Ca2+
concentrations (Figure 5).








B:III:8 Female 65 VPCs LVEDD 62
mm
8 VPCs Negative* 640 VPCs
B:IV:3 Female 34 VPCs Normal 46 VPCs N/A 5080 VPCs





C:III:10 Male 64 Normal Septum 12
mm
Normal Negative 190 VPCs
C:III:13 Male 64 Normal Septum 14
mm
Normal Negative 2 VPCs
C:IV:3 Female 48 Normal Normal 6 VPCs Negative 5 VPCs
C:IV:13 Female 43 Normal Normal Normal Positive 170 VPCs
LVEDD = left ventricular end-diastolic volume, VPC = ventricular premature complex. N/A= not available. * refers
to the normal epinephrine test, please see Methods.












































































4   CARDIAC CALCIUM CYCLING GENE MUTATIONS IN FAMILIAL VENTRICULAR
ARRHYTHMIAS RESEMBLING CPVT
A total of 33 symptomatic patients with frequent VPCs of unknown etiology were recruited to Study V.
The criteria for enrollment were as follows: frequent VPCs occurring during exercise and consecutive
VPCs, history of syncope, and/or sudden juvenile death in the family. None of the patients had structural
heart disease or prolonged QT interval. In 16 patients, VPCs were inducible solely upon exercise, while in
17 patients, VPCs occurred also at rest and at the recurring phase of exercise, thus differing from classical
CPVT. In both subgroups, an index patient had suffered from juvenile (( 40 years) sudden cardiac death.
Over the course of the study, 232 relatives underwent thorough clinical examination. Familial occurrence
of the disease phenotype was evident in 38% (n=6) and 41% (n=7) of the two subgroups.
The analysis of the exon 3 region of the RyR2 gene revealed two 1.1-kb genomic deletions in two CPVT
patients. The 33-year-old index patient in Family D (Figure 4) showed frequent bidirectional VPCs during
exercise typical of CPVT. Three family members had a similar symptomatic CPVT phenotype.
Interestingly, atrial fibrillation was observed in the index patient’s son and sister, but not in other relatives.
The sister also featured atrioventricular conduction abnormalities during follow-up. DNA analysis
revealed a 1.1-kb deletion of the RyR2 gene (c.168-301_c.273+722del1128), predicted to result in the
elimination of the highly conserved exon 3 and thus 35 amino acids (p.Asn57-Gly91) from the RyR2
protein. The 39-year-old index patient in Family E featured atrial fibrillation and multifocal VPCs during
the exercise stress test and developed increased trabeculation of the left ventricle suggestive of
noncompaction cardiomyopathy. His son showed a similar phenotype in the absence of atrial arrhythmias
and cardiomyopathy. The two patients carried the previously reported 1.1-kb deletion (c.168-
228_c.273+793del1126) (Bhuiyan et al. 2007b), which is expected to result in an in-frame deletion of 35
amino acids from the RyR2 protein similarly to the deletion identified in Family D.
The direct sequencing of the RyR2 gene revealed two novel RyR2 mutations, S616L and R1051P,
underlying typical CPVT. The RyR2 S616L mutation arose de novo in a female adolescent (Family F,
Figure 4), while the RyR2 R1051P was identified in a 35-year-old father and his son (Family G, Figure 4).
The 35-year-old index patient also featured lateral ST alterations in ECG, but only a minor septal
hypertrophy of 13 mm in the echocardiography. In addition, a novel RyR2 variant N3308S, detectable in
one of the 600 control alleles, was evident in a 34-year-old female patient with frequent resting VPCs
(Family H, Figure 4). She presented with over 20 000 predominantly single VPCs, but also salvos of up to
four successive beats in the 24-h ECG recording. Two of the descendants carried the RyR2 N3308S, but
showed no abnormalities in clinical evaluation. The single-channel recordings of the RyR2 N3308S did
not reveal enhanced probability to cytosolic Ca2+ compared with the wild-type channels (Figure 5).
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As the majority of patients recruited to the study did not have disease-causing mutations in the RyR2 gene,
the probands were screened for putative candidate genes that affect calcium cycling in the cardiac
myocyte, and could therefore result in a disease phenotype identical to CPVT. The direct sequencing of
genes coding for calstabin/FKBP12.6 (FKP1B) and sodium-calcium exchanger/NCX1 (SLC8A1) did not
reveal any genetic variants leading to amino acid alterations. A novel polymorphism, T982M, was
identified in the ATP2A2 gene encoding the sarcoplasmic reticulum Ca2+ ATPase, also known as
SERCA2a, with a nonsignificant frequency difference among probands and controls.
5   SURVEY OF SCN5A MUTATIONS IN BRUGADA SYNDROME
Of the six patients featuring ECG patterns suggestive of Brugada syndrome, two were identified to carry
mutations in the SCN5A gene (unpublished data). The mutation SCN5A E1784K was identified in a 51-
year-old index patient (Family I, Figure 4), who was resuscitated from ventricular fibrillation. The
baseline ECG showed a typical type 2 Brugada ECG with a 2-mm ST segment elevation in precordial
leads V1-V2 followed by positive T waves. The QTc interval was prolonged to 530 ms. Altogether, three
relatives carried the same mutation and featured varying degrees of cardiac abnormalities in the clinical
evaluation. The index patient’s son, aged 22 years, had a similar type 2 Brugada ECG pattern with
biphasic T waves in precordial leads and QTc interval prolongation of 460 ms. The other son featured
normal baseline ECG and ST segment elevation upon exposure to flecainide, but the electrophysiological
studies were normal. The index patient’s brother, whose DNA was not available, had died suddenly and
unexpectedly at the age of 30. The daughter of the deceased brother featured no evidence of Brugada
syndrome in clinical examinations, but showed an abnormal QTc interval duration of 490 ms in baseline
ECG and excess prolongation of the QT interval in the 24-h ECG recording at slower heart rates,
suggestive of a LQTS3 phenotype. The mother of the index, also a carrier of the familial gene defect, was
unavailable for clinical examination. Patients featuring clinical Brugada syndrome or LQTS3 have been
treated with ICDs. In Family J (Figure 4), the only affected individual showed Brugada-type ECG with
ST segment elevation, normal QTc interval, paroxysmal atrial fibrillation, and sinus node dysfunction,
and carried splice site mutation SCN5A IVS21+16G>A, predicted to result in disruption of the correct
splicing in the corresponding mRNA.
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DISCUSSION
1   PREVALENCE OF LQTS IN FINLAND
LQTS is generally a rare disorder, with recent prevalence estimates of 0.01% (Ackerman et al. 2003) to
0.05% (Hofman et al. 2007). In Finland, the four previously identified founder mutations, KCNQ1 G589D,
KCNQ1 IVS7-2A>G, KCNH2 L552S, and KCNH2 R176W, have been shown to explain up to 40-70% of
the genetic spectrum of congenital LQTS (Piippo et al. 2001, Fodstad et al. 2004). Therefore, it is hardly
surprising that these mutations also underlie a considerable proportion of cases with antiarrhythmic-
induced torsades de pointes arrhythmias, as shown in Study I. The presented 19% frequency of disease-
causing LQTS gene mutations underlying acquired LQTS is considerably more than the previously
reported frequency of 5% in other populations (Yang et al. 2002, Paulussen et al. 2004) and is likely to
reflect the genetic composition of Finnish people. However, the limited study sample precludes any
statements regarding the prevalence and nature of concealed congenital LQTS in drug-induced TdP in
Finland. Nevertheless, the Study I does provide further evidence that congenital LQTS gene mutations
may underlie acquired LQTS. In agreement with earlier studies, up to 40% of the study subjects showed a
QTc < 470 ms before drug exposure, suggesting that the risk for proarrhythmia is not always predictable
from baseline ECG.
Taking advantage of the unique constellation of inherited LQTS in Finland, we aimed at estimating the
actual prevalence of LQTS founder mutations using a large population-based sample of over 6000
individuals representing the entire population of Finland aged 30 years or more. The calculated
prevalence estimate of 0.4% is striking and suggests that 20 000 of the 5.2 million inhabitants in Finland
may be genetically predisposed to severe ventricular arrhythmias. Even after excluding the 16 carriers of
KCNH2 R176W with a milder QT-prolonging effect, the prevalence estimate of 0.2% (95% CI 0.1-0.3%)
is considerably more than generally expected. As the study population did not include subjects younger
than 30 years and the analysis was targeted only to the four founder mutations, the actual prevalence of
LQTS is likely to be even higher. This finding is not only of national interest, but provides an example for
population-based screening to identify individuals with a potential risk of arrhythmias. Since the analyzed
LQTS founder mutations are specific to the Finnish population, the results cannot be extrapolated to other
populations.
In addition to the prevalence estimates, the effect sizes of mutant alleles on QT interval prolongation
were assessed. The described effect sizes of 22-50 ms are substantial, but caution must be employed in
translating this information to arrhythmia susceptibility. Data on LQTS risk stratification have derived
from clinical LQTS samples only, and therefore, no direct evidence of the causality of these mutant
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alleles to ventricular arrhythmias exists at the population level. In the clinical LQTS founder mutation
samples, the mean QTc intervals are somewhat higher (Fodstad et al. 2004) than in the carriers from the
Health 2000 Study. Logically, the overt congenital LQTS correlates with longer QT intervals, but clinical
LQTS patients may also possess other as yet unidentified genetic factors that affect the QT interval, and
thus, the disease phenotype. Despite their potential to cause a life-threatening form of LQTS, the Finnish
founder mutations may lead to milder phenotypic effects than disease-causing LQTS mutations in
general. Of the founder mutation carriers in clinical samples and their genetically screened relatives, 23-
38% are symptomatic (Fodstad et al. 2004), but the proportion is likely to decline as more distant,
probably asymptomatic relatives are evaluated. In addition, the penetrance of the founder mutations is
incomplete, ranging from 21% to 34% (Fodstad et al. 2004) (Laitinen et al. 2000) in the clinical LQTS
families.
The KCNH2 R176W mutation requires particular attention since it has been reported as an innocent
polymorphism in other populations (Ackerman et al. 2003, Mank-Seymour et al. 2006). The updated
information on the 112 Finnish KCNH2 R176W mutation carriers identified to date reveal symptoms in
16 (14%) of the mutation carriers and a prolonged QT interval in 40% of male and 22% of female mutant
allele carriers (Study II). Previously, the KCNH2 R176W has also been identified in compound
heterozygous carriers of the KCNQ1 G589D mutation, with longer QTc intervals and more frequent
arrhythmia symptoms than the KCNQ1 G589D carriers alone (Fodstad et al. 2006). The 22-ms effect size
of the KCNH2 R176W on the age-, sex-, and heart rate-adjusted QT interval and the estimated frequency
of 0.3% in the Finnish population are in accordance with previous studies that have suggested that
KCNH2 R176W is a potentially disease-causing population-prevalent modifier of Finnish LQTS
(Fodstad et al. 2004). Considering the substantial QT-prolonging effects of these LQTS founder
mutations in the background population, it is evident that these individuals are at increased risk of
developing arrhythmias if the repolarization reserve (Roden 2006) is further challenged by exposure to
QT-prolonging medication and hypokalemia, in particular (Roden 2004).
2   COMMON GENETIC MODIFIERS OF CARDIAC REPOLARIZATION
KCNE1 D85N
Previously, KCNE1 D85N has been shown to be associated with acquired LQTS in patients with
unrecognized disease-causing mutations in other LQTS genes (Wei et al. 1999b, Paulussen et al. 2004,
Mank-Seymour et al. 2006). In addition, the minor N85 allele has been shown to be associated with
prolonged QTc interval in a limited sample of LQTS1 and LQTS2 patients (Westenskow et al. 2004).
Further evidence is provided by Gouas et al, who studied 200 individuals featuring the longest and
shortest QTc intervals in an original study population of nearly 4000 French individuals (Gouas et al.
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2005). They reported increased odds of the minor N85 allele carriers being in the longer QTc interval, but
the significance level remained borderline (p=0.03) considering the number of SNPs tested in the study.
Study IV provides convincing evidence that the KCNE1 D85N variant, present in 2.6% of the Finnish
population, is associated with QT interval duration and results in a 10-ms increase in the age-, sex-, and
heart rate-adjusted QT interval per each minor allele copy.
KCNH2/HERG variants
In addition to the KCNE1 D85N association, Study III replicated the QT-modulating effect of two
KCNH2 variants. After the initial description of the KCNH2 K897T (Laitinen et al. 2000), marked
attention has been raised to fully understand the consequences of the polymorphism. Several population-
based studies have reported associations of the SNP with QT interval shortening, with varying degrees of
statistical significance (Bezzina et al. 2003, Gouas et al. 2005, Pfeufer et al. 2005, Newton-Cheh et al.
2007). Conflicting results also exist (Pietila et al. 2002, Koskela et al. 2008). A limited study sample of
randomly selected middle-aged healthy Finnish women shows an opposite QT-prolonging effect of the
minor T897 allele (Pietila et al. 2002). Furthermore, compound carriers of the KCNH2 T897 allele and a
KCNQ1 G589D mutation showed longer QT intervals than mutation carriers with the wild-type KCNH2
K897 allele during a maximal exercise stress test (Paavonen et al. 2003). The intronic KCNH2 rs3807375
was previously shown to be associated with increased QT duration among participants of the Framingham
Heart Study (Newton-Cheh et al. 2007). In addition, this SNP shows linkage to the QT-prolonging variant
KCNH2 rs3815459 (Pfeufer et al. 2005). Taken together, the majority of the available data suggest that
KCNH2 K897T has a QT interval-shortening effect in baseline conditions, while the intronic KCNH2
rs3807375 variant appears to modulate the baseline QT interval in the opposite direction in the general
population.
NOS1AP variants
Common genetic variants in the NOS1AP gene coding for the neuronal nitric oxide synthase regulator
CAPON were first demonstrated to be associated with QT interval duration in the German-based genome-
wide KORA study (Arking et al. 2006). Several NOS1AP variants have subsequently been reported to be
associated with modest QT interval prolongation in ten independent population-based samples (Arking et
al. 2006, Aarnoudse et al. 2007, Post et al. 2007, Tobin et al. 2008, Arking et al. 2009, Raitakari et al.
2009)(Study IV) and also in multiethnic pedigrees showing enrichment of type 2 diabetes (Lehtinen et al.
2008). The evidence based on genetic association studies is convincing, but the molecular mechanisms of
brain-enriched CAPONs on myocardial repolarization remain largely unknown. Very recently, Chang et
al. showed that CAPON is expressed in the myocardium, interacts with NOS1, and accelerates cardiac
repolarization by inhibition of L-type calcium channels and resulting enhancement of IKr (Chang et al.
2008). NOS1 has also been demonstrated to affect cardiac contractility (Barouch et al. 2002, Burkard et al.
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2007, Oceandy et al. 2007), and CAPONs may also have other as yet unidentified biological effects on
cardiac ion channels (Chang et al. 2008).
Other LQTS variants of uncertain significance
In Study III, effect sizes of several LQTS variants on QT interval duration did not reach statistical
significance. These variants, including KCNH2 R1047L, SCN5A R190G, SCN5A A572D, KCNE1 G38S,
and KCNE2 T8A, seemingly do not modulate baseline QT interval duration in the Finnish population. In
addition, the null effects of KCNE1 G38S (Akyol et al. 2007, Gouas et al. 2007) and KCNE2 T8A
(Pfeufer et al. 2005) have been confirmed in other populations. However, whether these variants act on
cardiac repolarization upon exposure to other extrinsic factors, such as exercise, hypokalemia, ischemia,
or QT-prolonging medications, remains obscure (Roden 2004).
In addition, the effect of SCN5A H558R on QT interval under basal conditions remains unsettled. Since
SCN5A contributes to a set of ion channelopathies, the SCN5A H558R has been studied in clinical patient
populations featuring lone atrial fibrillation (Chen et al. 2007) and the Brugada syndrome (Poelzing et al.
2006). Its effect on cardiac repolarization at the population level is somewhat unclear, as the only existing
evidence comes from the French DESIR study with borderline statistical support (p=0.01) (Gouas et al.
2005). Considering the nature of the genetic association studies with multiple SNPs, the need for p-values
less than 10-5 or 10-6 is widely acknowledged (Newton-Cheh et al. 2005). Therefore, Study III cautiously
interprets the existing evidence of the SCN5A H558R association with QT interval with a p-value of 10-3
to be inconclusive.
Clinical impact of common genetic variants
Despite the significance levels, the actual allelic effects of the common KCNH2 K897T and rs3807375 as
well as the NOS1AP rs2880058 variant remain relatively modest, as reflected by the low R2 values of the
linear regression models. Presumably, these common variants cannot individually account for the
population burden of QT prolongation or the increased risk of arrhythmias. In addition, extrapolating
these results to other populations must be done cautiously since the association studies have been
performed in study samples of European ancestry only. The construction of the QT-prolonging score
attempted to estimate the combined effect of these SNPs on QT interval in addition to the KCNE1 D85N
variant. The 10-ms difference between the QT intervals of the first and fifth quintiles of the QT-
prolonging score is comparable with the QT-prolonging effect of drugs withdrawn from the market by
pharmaceutical companies (De Ponti et al. 2002), and thus, of potential clinical relevance. Since QT
interval prolongation is associated with increased mortality in patients with coronary artery disease
(Schwartz et al. 1978, Puddu et al. 1986) and in the general population (Algra et al. 1991, Schouten et al.
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1991, Karjalainen et al. 1997), even small additive changes caused by common variants may contribute to
increased risk of arrhythmias at the population level.
3   PHENOTYPIC AND GENOTYPIC VARIABILITY IN CPVT-RELATED DISORDERS
3.1   Exon 3 deletion in the RyR2 gene
The identification of two analogous 1.1-kb RyR2 exon 3 deletions in two patients with CPVT phenotype
(Study V) suggests that this region may be of importance in the pathogenesis of inherited arrhythmia
disorders. The corresponding in-frame deletion of 35 amino acids in the RyR2 protein was previously
characterized by Bhuiyan et al. in two families with exercise-related ventricular arrhythmias, atrial
arrhythmias, conduction defects, and left ventricular dysfunction (Bhuiyan et al. 2007b). Our patients
featured a classical CPVT phenotype in the absence of consistent evidence for RyR2-related atrial
arrhythmias and/or structural abnormalities. However, the identification of RyR2 exon 3 deletions
independently in altogether four kindreds thus far suggests that this region may provide a target for
molecular genetic studies in CPVT-related disorders.
3.2 RyR2 missense mutations
Upon investigating 19 cases of sudden cardiac death in Study IV, two novel RyR2 mutations were
identified in deceased individuals. The clinical evaluation of RyR2 mutation carriers in family members
revealed phenotypes not typical for CPVT. The only available carrier of RyR2 G2145R did not feature
any abnormalities in the maximal exercise stress test, which, however, does not exclude the possibility
that this mutation is a cause of classic CPVT. The penetrance of CPVT-linked RyR2 mutations is high, up
to 80-90%, but not complete (Swan et al. 1999a).
In addition to RyR2 G2145R, RyR2 R3570W, detected independently in two deceased individuals,
showed divergent phenotypic profiles among the mutation carriers. First, the two deceased individuals
featured left ventricle dilatation and mild hypertrophy at autopsy, which were also apparent in a milder
form in four surviving relatives. Previously, CPVT has been classified as an arrhythmogenic disorder of
an intact myocardium, to distinguish it from arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC/D), which, in addition to ventricular tachycardia, features enlargement of the ventricles and
replacement of myocardium by fibrofatty tissue (Nava et al. 1988). In fact, it has been suggested that
these diseases represent allelic disorders (Tiso et al. 2001). However, the finding of the integral role of
desmosomal genes in ARVC pathogenesis (Sen-Chowdhry et al. 2007) implies that RyR2-linked ARVD2
represents CPVT with mild structural abnormalities.
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As cited above, a recent study of two kindreds featuring exercise-related ventricular arrhythmias, atrial
fibrillation, conduction defects, and occasional left ventricular dysfunction revealed a 1.1-kb genomic
RyR2 deletion (Bhuiyan et al. 2007b). Interestingly, one of the study subjects featured ventricular
arrhythmias in resting conditions (Bhuiyan et al. 2007b). Similarly, in the extended pedigree analysis of
the RyR2 R3570W mutation carriers, two surviving relatives featured ventricular arrhythmias unrelated to
exercise. In addition, Study V revealed a rare RyR2 N3308S variant with no demonstrable in vitro effect
on RyR2 channel activity in a patient with frequent VPCs in resting conditions. The clinical significance
of the variant remains uncertain, but RyR2-linked cardiac disorders evidently represent extended
phenotypes from resting and exercise-induced ventricular arrhythmias to varying degrees of structural
abnormalities of the heart.
Since the clinical findings of the surviving RyR2 R3570W mutation carriers were scanty, the causality of
the gene defect in sudden cardiac death and in the low-penetrant expression profiles of the surviving
mutation carriers remains disputable. Identification of amino acid-altering mutation RyR2 R3570W
independently in two victims of SCD in a gene linked to a highly malignant arrhythmia disorder makes
hypothesis of a causal role justifiable. However, since the carriers of the mutation appeared to be distant
relatives, other genetic factors contributing to the SCD cannot be ruled out. This further challenges the
risk assessment of the surviving RyR2 R3570W mutation carriers that do not represent overt CPVT. In the
era of high-throughput genotyping, the results of Study IV emphasize the value of comprehensive
molecular genetic and clinical assessments of mutation carriers and available family members.
Several other limitations apply to Studies IV and V. Neither study was designed to define the prevalence
of RyR2 gene mutations in SCD and other CPVT-related disorders. The investigated phenotypes are rare
and the resulting small sample sizes preclude any definitive statements of the occurrence of rare
mutations in these candidate genes in other study populations. Since Study IV reports the results of
victims of SCD referred by different forensic medicine physicians, data may be adversely affected by
individual definition and referral bias. Despite the uniform inclusion criteria of Study V, the survey
represents a heterogeneous group of patients with frequent VPCs of unknown etiology. Nevertheless,
elucidating the genetic background of this heterogeneous group is essential so that the severe forms of the
disorder can be identified.
3.3   Other genes affecting cardiac calcium signaling
An average of 40% of the CPVT patients carry identifiable RyR2 mutations (Kontula et al. 2005). It was
hypothesized that mutations in FKBP1B, ATP2A2, or SLC8A1 could explain the genetics of CPVT
patients lacking mutations in the coding regions of the RyR2 gene. Several in vitro and murine
experiments have supported the role of depleted FKBP12.6 in generating a gain-of-function defect in
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mutant ryanodine channels and therefore delayed afterdepolarizations (DADs) and arrhythmias (Lehnart
et al. 2004). However, controversial findings support a calstabin-independent mechanism where a Ca2+
overload in the sarcoplasmic reticulum leads to Ca2+ spillover waves via RyR2 channels (Jiang et al.
2002, George et al. 2003, Jiang et al. 2004, Xiao et al. 2004, Jiang et al. 2005). The abnormal Ca2+
cycling and sarcoplasmic reticulum content in CPVT pathogenesis imply that also SERCA2a/ATP2A2,
playing a central role in cardiac excitation-contraction coupling, could be a plausible candidate gene for
severe arrhythmic disorders. In addition, a zebrafish model provides evidence that loss-of-function
mutations in cardiac SLC8A1 encoding the sodium-calcium exchanger (NCX1) may lead to intracellular
Ca2+ imbalance irrespective of membrane depolarization or catecholaminergic stimulus (Langenbacher et
al. 2005). Due to the limited sample size in Study V, the pathogeneity of these integral cardiac calcium
signaling genes in other study populations cannot be ruled out. However, a majority of the patients
featuring frequent VPCs of unknown etiology did not exhibit mutations in RyR2, FKBP1B, ATP2A2, and
SLC8A1 genes in this study, thus reflecting the complex genetic background of CPVT-related disorders.
3.4   Heterogeneity of in vitro effects of mutant RyR2 channels
The single-channel recordings of the mutant RyR2 G2145R revealed an increased open probability to
upper systolic cytosolic Ca2+ concentration over 1 *M [Ca2+]. The gain-of-function defect occurs
independently of PKA hyperphosphorylation and calstabin depletion. Similarly, the RyR2 R3570W
resulted in a leftward shift in the Ca2+-dependence curve without the effect of circulating catecholamines.
The gain-of-function defect persisted from the physiologic lower diastolic to upper systolic Ca2+
concentrations. Presumably, the arrhythmia-triggering Ca2+ leak via SCD-linked RyR2 mutant channels
occurs due to a relative Ca2+ overload of the sarcoplasmic reticulum. Alternatively, the persistent
sarcoplasmic reticulum Ca2+ leak may activate other Ca2+ signaling pathways, resulting in the mild
cardiomyopathy observed among carriers of RyR2 R3570W. Since a number of SCD-linked RyR2
mutation carriers did not feature abnormalities in the clinical evaluation, other predisposing factors are
necessary for a lethal event to occur. Male gender may be a contributing factor, consistent with
suggestions of previous studies on CPVT (Priori et al. 2002c). The present data reinforce earlier
assumptions that the mutant RyR2 channels result in multiple functional consequences in vitro, and that
the mutational locus may be one determinant of these effects.
4   PHENOTYPIC VARIABILITY OF SPECIFIC SCN5A MUTATIONS
The SCN5A E1784K is the most common single LQTS3 mutation, and it has previously been identified to
cause LQTS3 in a Finnish family (Fodstad et al. 2004) and in multiple families worldwide (Wei et al.
1999a, Splawski et al. 2000, Tester et al. 2005b). It has also been reported to underlie Brugada syndrome
in a single Caucasian family (Priori et al. 2002b). Very recently, a multicenter study aimed to determine
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whether diverse biophysiological properties explained the variety of clinical phenotypes encountered
among SCN5A E1784K carriers (Makita et al. 2008). In evaluation of a cohort of 15 kindred and 44
SCN5A E1784K mutation carriers, the majority of study participants (93%) showed a LQTS3 phenotype,
but overlapping Brugada syndrome (22%) and sinus node dysfunction (39%) were also present (Makita et
al. 2008). The delicate in vitro analyses revealed that the SCN5A E1784K mutation leads to a negative
shift of the steady state of the Na+ channel inactivation and to enhanced tonic block of sodium channel
antagonists that explain the extended phenotypes among the mutation carriers (Makita et al. 2008). These
in vitro functional results are congruent with previous reports showing similar functional defects in other
SCN5A mutations, resulting in the mixed phenotypes (Bezzina et al. 1999, Veldkamp et al. 2000,
Viswanathan et al. 2001). The identification of the SCN5A E1784K mutation in a Finnish family showing
characteristics of Brugada syndrome and QT interval prolongation typical of LQTS3 (Marjamaa et al.,
unpublished data) provides further evidence that the mixed phenotypes are common in SCN5A
channelopathies and may occur even within a single family.
5   GENETIC TESTING OF INHERITED ARRHYTHMIA DISORDERS
The last decade of molecular genetics has provided a valuable tool for clinicians in diagnostics of
inherited arrhythmia disorders. Genetic screening of family members potentially at risk of developing a
disease phenotype enables identification of individuals at the early, often pre-symptomatic phase. This is
of particular interest in inherited ventricular tachyarrhythmia syndromes, such as LQTS and CPVT, where
clinical follow-up and lifestyle modifications, such as avoidance of certain medications, electrolyte
disturbances, and strenuous exercise, can effectively avert risk for sudden cardiac death (Zipes et al.
2006). The three most common LQTS genes responsible for LQTS subtypes 1-3 are estimated to account
for 75% of the genetic spectrum of LQTS (Splawski et al. 2000, Tester et al. 2005b). However, genetic
screening at the population level has not been considered practical owing to the genetic complexity and
rarity of inherited arrhythmia disorders, and thus, the high costs of screening.
Since LQTS is enriched in the Finnish population and the four Finnish LQTS founder mutations account
for the majority of the known genetic spectrum of the disorder, population screening of LQTS founder
mutations may become cost-effective in Finland along with the rapidly developing genetic screening
measures. In addition, identification of the minor allele carriers of the KCNE1 D85N, leading to a
significant QT-prolonging effect in the general population, could mark individuals at increased risk for
repolarization-related arrhythmias. As evidenced in the Study III, the four polymorphisms showing
statistically significant QT-modulating effects (i.e. KCNH2 K897T, KCNH2 rs3807375, KCNE1 D85N,
and NOS1AP rs2880058) collectively account for a potentially important QT interval prolongation and
could therefore be useful in identifying individuals at increased arrhythmia susceptibility. The exon 3
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The four Finnish LQTS founder mutations KCNQ1 G589D, KCNQ1 IVS7-2A>G, KCNH2 L552S, and
KCNH2 R176W are surprisingly prevalent in the Finnish population. These mutations lead to
considerable QT interval prolongation also at the population level and may thus contribute to increased
risk of repolarization-related arrhythmogenesis. This unique enrichment of LQTS in Finland provides
excellent research opportunities to study the genetic modifiers and environmental factors contributing to
the divergent clinical phenotypes of the mutant allele carriers. In addition, the limited number of enriched
variants provides a rationale for assessing whether genetic testing and early identification of the mutant
allele carriers could become cost-effective for the Finnish healthcare system.
KCNE1 D85N minor allele, present in 1.4% of the Finnish population, is associated with a considerable
QT interval prolongation in the general population, and could thus identify individuals at increased risk
for arrhythmias in the background population, but may also represent a modifier factor of clinical LQTS.
KCNH2 K897T, KCNH2 rs3807375 and NOS1AP rs2880058 variants were confirmed to show a modest
QT-modulating effect at the population level, similarly to other populations.
RyR2 missense mutations are detectable in a series of sudden cardiac death patients. However, not all
RyR2 mutations lead to a typical CPVT phenotype with exercise-induced ventricular tachycardia in a
structurally normal heart. Large genomic RyR2 deletions comprising exon 3 provide a target for future
genetic studies in RyR2-mediated arrhythmia disorders.
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